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ABSTRACT 
 
 
Purpose: Numerous studies have identified stem-like cells, termed cancer stem cells 
(CSCs), in breast tumors and established cell lines. It has been hypothesized that CSCs 
are responsible for breast cancer formation, progression and recurrence; therefore, a 
deeper understanding of the signaling pathways regulating CSC survival will benefit 
development of novel therapeutic strategies. Notch signaling, which is dysregulated in 
breast cancer and has been implicated in mammary stem cell self-renewal, and can be 
effectively blocked by gamma-secretase inhibitors (GSIs). While GSIs are currently in 
clinical trials for breast cancer, it is not fully understood how these compounds will affect 
CSCs or if CSCs from different breast cancer phenotypes (estrogen receptor-alpha 
(ERα)-positive, ERα–negative, Her2/neu overexpressing) will be differentially affected.  
Experimental Design: The stem cell-like population was isolated using several different 
methods including side population, mammosphere formation and aldehyde 
dehydrogenase activity (Aldefluor). Notch pathway activity was analyzed in CSCs 
derived from cell lines and primary tumors of different breast cancer phenotypes using 
quantitative reverse transcriptase-polymerase chain reaction (RT-qPCR) and confirmed 
by Western blotting. The effect of Notch inhibition on secondary mammosphere 
formation and colony formation in soft agar was evaluated. Furthermore, apoptosis was 
confirmed after treatment with one GSI, MRK003, by TUNEL assay and Annexin V - 
propidum iodide staining. The mechanism of apoptosis was explored utilizing a RT-
qPCR based approach as well as several kinase inhibitors including those that inhibit c-
Jun N-terminal kinase and the p38 mitogen activated kinase.  
    
xix 
Results: The CSCs possessed elevated levels of Notch activation compared to the non-
CSCs regardless of breast cancer phenotype, sample origin (cell culture or primary 
tumor) or method of isolation / enrichment. Blockade of Notch signaling with three 
structurally distinct GSIs, a specific Notch decoy protein or an siRNA targeting Notch-1 
abolished secondary mammosphere formation and/or blocked colony formation in soft 
agar and decreased the side-population.  
Conclusions: These findings support a role for Notch signaling in CSC self-renewal and 
proliferation, and they suggest Notch inhibition may have clinical benefits in targeting 
CSCs. Furthermore, our data shows that Notch may be important in the survival of 
mammospheres and the c-Jun N terminal kinase and/or p38 MAPK pathway may play a 
role in MRK003- induced apoptosis. 
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CHAPTER 1 
INTRODUCTION 
 
Normal Development of the Breast 
The mammary epithelia consists of a network of ducts which branch and invade 
the mammary fat pad before birth (1-6). During puberty the ducts start to branch due to 
hormone stimulation. At this phase, rapid growth is observed in the ducts. In some 
places, the ducts will stop growing and form structures called terminal end buds. After 
puberty, these buds will differentiate to form alveolar buds (this requires hormonal 
stimulation) (7). With pregnancy and lactation, lobulo-acinar structures form; these 
contain alveolar cells responsible for the secretion of milk. Then at weaning, apoptosis 
occurs, and the gland returns to its former, pre-pregnancy structure (3).  
 
There are two different types of cells in the mammary gland: luminal cells, which 
line the ducts and lobules and myoepithelial cells, which line the basement membrane. 
Several markers are used to identify the luminal cells including cytokeratins (CK) -5, -7, -
18, -19, the estrogen receptor (ER), and the progesterone receptor (PR). Myoepithelial 
cells are characterized by a different set of markers including laminin, CD10, and CK-5, -
14, and -17; they do not express the ER (8). Figure 1 shows the structure of the terminal 
end bud along with the different cell types discussed.  
 2
The development of the mammary gland is regulated by hormone production and 
by small peptides produced by either stromal or epithelial cells including: Receptor
Activated by Nuclear Factor-Kappa B (NF-κB) ligand (RANKL, osteoprotegerin ligand) 
(9), members of the Hedgehog family (10), and Transforming Growth Factor-beta (TGF-
β) families (11). In the breast, the absence of RANKL causes a lack of proliferation and 
differentiation of the alveolar buds even though the mammary gland forms normally up to 
that point. This means lactation is not possible in the absence of RANKL. To illustrate 
this point, pregnant RANKL-/- mice were unable to lactate until RANKL was implanted. 
TGF-β3 has been shown to be involved in apoptosis that occurs immediately after 
weaning. Specifically, after milk production ceases, TGF-β3 is significantly upregulated 
in the mammary epithelium, which precedes apoptosis (11). The upregulation is due to 
milk stasis, not hormonal changes. Once initiated, apoptosis occurs through the 
alteration of cell cycle genes such as c-jun, c-fos, c-myc, and caspases, as well as, Bax 
and Bcl-Xs (apoptosis promoting factors) (11). The Hedgehog pathway is also involved 
in many developmental processes including skin, limbs, lung, eye, and nervous system 
among others. The ligand Hedgehog binds to the receptor Patched, which then activates 
the downstream target Smoothened that is responsible for activation of the Gli family of 
transcription factors (Gli1, Gli2, and Gli3) leading to target gene expression. Lewis et al. 
determined that a haploinsufficiency at the Patched locus leads to defects in ductal 
structures, as well as, minor changes in the terminal end buds in heterozygous post-
pubescent virgin animals. These defects are reverted during lactation but return during 
gland development (10). 
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Estrogen and the Estrogen Receptor  
Estrogen and the ER play an important role in normal breast development. Both 
are required for proliferation during the menstrual cycle and pregnancy (12). The ER is a 
steroid hormone receptor that belongs to a family of nuclear receptors (13). It is mainly 
found in luminal epithelial cells located in the lobules and is not found in cells expressing 
the basal marker called common acute leukemia lymphoblastic antigen (CALLA) (14). 
There are two isoforms of the receptor: ERα and ERβ. ERα has been extensively 
studied and is made up of several different domains, one of which is the ligand-binding 
domain (which contains the activation function-2 domain (AF-2), (Figure 2). The ligand 
17-β estradiol (also referred to as estradiol) is a lipophilic molecule that enters the cell 
through the membrane and binds to the ligand-binding domain of the ER. This allows the 
Figure 1: The Terminal End Bud. The diagram shows the duct and terminal end 
bud. The duct is lined with differentiated luminal epithelial cells that are supported 
by myoepithelial cells and extracellular matrix. The terminal end bud forms starting 
with the cap cells (terminal end bud stem cells), which differentiate into 
myoepithelial cells. Body cells will differentiate into luminal cells. As the duct 
elongates apoptosis occurs in the body cells, which forms the lumen. Figure 
modified from Smalley et al. (2). 
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ER to dimerize and bind to specific estrogen response elements in the promoters of 
various genes. Estradiol plays a role in the growth and differentiation of the female 
reproductive organs (15). Specifically, estrogens will regulate growth and differentiation 
of various tissues in the body (16). When estradiol binds to the receptor a conformational 
change occurs whereby helix 12 of ERα binds to helices 3, 5/6 and 11 allowing for the 
activation of the ligand-binding domain. Once the ligand binds to the receptor several 
transcriptional co-activator proteins including: steroid receptor co-activators (SRC-1) and 
GRIP1 (SRC-2) will bind to the ligand- binding domain (17, 18). In general, estradiol 
induces expression of genes involved in cell cycle regulation including cyclin A, cyclin D1 
and survivin; and downregulates genes associated with apoptosis such as caspase 2 
and caspase 9 among others (19). Another domain, AF-1, is regulated by growth factors, 
which use the mitogen activated protein kinase (MAPK) pathways (20).  
 
 ERβ was originally cloned by Kuiper et al. in 1996 (21). Its structure is similar to 
ERα, but the ligand-binding domain has only 59% homology with ERα. The AF-1 regions 
are quite dissimilar with 16% homology, but the DNA binding domain had 97% homology 
between the two receptors (21, 22) (Figure 2). The role of ERβ in breast development is 
unclear. One study suggests that ERβ may repress ERα function, which would make 
ERα insensitive to hormones during lactation (23). With respect to cancer, another study 
showed that ERβ mRNA levels were decreased in invasive carcinomas compared with 
the normal mammary tissue (24). Recent evidence suggests that ERβ may have a 
protective role against breast cancer development. In fact, in many breast tumors ERβ 
has been lost, probably due to methylation of its promoter, which is common in cancer. 
This suggests ERβ may be a tumor suppressor (reviewed in (25)).  
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The Progesterone Receptor 
The progesterone receptor (PR) is also important in breast development and is believed 
to be responsible for the formation of the lobo-alveolar structures during pregnancy. It is 
also likely responsible for the proliferation and differentiation of cells during lactation. PR 
activation is very similar to that of the ER. It involves binding of progesterone, 
dimerization of the receptor, binding to the progesterone response element and 
transcription of various genes including cyclin D1, cyclin dependant kinases, c-fos, and  
c-myc (26). 
 
Stem Cells in Normal Breast Development  
Stem cells are important in the development of the mammary gland, and it is 
believed that the terminal end buds contain stem cell activity. These cells, called cap 
cells, will elongate the terminal end buds and give rise to the myoepithelial layer, while 
cells called “body cells” will give rise to the luminal epithelial cells. These cells will 
Figure 2: Structure of Estrogen receptor-alpha and estrogen receptor beta. 
Homology between the two receptors is shown as a percentage. Numbers 
above each structure represent amino acid numbers. The receptor contains 
a DNA binding region and a ligand-binding domain. The activation function 
domains -1 and -2 (AF-1 AF-2) are found within the A/B and E/F regions 
respectively. Modified from Matthews and Gustafsson (1).  
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undergo apoptosis and give rise to the lumen. Cap cells also have the ability to migrate 
into the lumen (Figure 1) (reviewed in (2)). After pregnancy and weaning, the mammary 
gland reverts to the pre-pregnancy state via apoptosis. Therefore, in subsequent 
pregnancies, a source of new cells must be present in the normal mammary gland to re-
form the alveolar structures needed for lactation. Mammary stem cells fill this role (3).  
 
Several studies have been done in mice that support the presence of stem cells 
in the mammary gland. One study by Daniel et al. used transplantation of small epithelial 
fragments into the mammary fat pad of mice (27). They demonstrated that a fully 
functional mammary gland could be generated from these fragments. They also showed 
that these fragments could be serially transplanted up to four times to form a functional 
mammary gland (27). Next, Kordon and Smith used mammary epithelium marked with 
mouse mammary tumor virus (MMTV) and showed that clonally dominant populations 
were responsible for generating a fully functional mammary gland (28). Also, in 2002, 
Welm et al. used BrdU labeling, immunosorting and transplantation to identify a 
population of stem cells that could regenerate the mammary gland (29). These cells 
were positive for the murine stem-cell antigen SCA-1, and could exclude a nuclear dye, 
Hoescht, a characteristic of stem cells (30, 31). Finally, in 2006, Shackleton et al. found 
that a mammary gland could be generated in mice from a single stem cell (identified by 
markers Lin- CD29hi CD24+) (32). They could then re-isolate the stem cells from the 
newly formed mammary gland, implant them into naïve mice, and form another 
functional mammary gland. 
 
Dontu et al. proposed a theory on the origins of ERα-positive and negative cells 
in normal human breast development. In normal breast development, an ERα-negative 
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stem cell generates both myoepithelial and ductal epithelial progenitor cells, which is 
consistent with the observation that estrogen stimulation is not required for early 
mammary gland development (33). The ERα-negative stem cell can differentiate into 
either ERα-negative or ERα-positive progenitor cells; ERα-positive progenitors will 
proliferate in response to estrogen later in development. When estrogen levels 
decrease, proliferation will cease. ERα-positive progenitor cells can form more 
differentiated ERα-positive or ERα-negative cells. Some evidence that supports this 
theory includes the fact that ERα-positive cells were not found in utero in the human 
mammary gland until about 30 weeks. In ERα-knockout mice there was no ductal or 
lobo-alveolar growth observed and terminal end buds did not form (33).  
 
Breast Cancer Relapse and Resistance 
Breast cancer is one of the leading causes of death in women with about 40,000 
deaths each year in the USA alone (34). A large part of mortality is due to the 
development of multidrug resistance by cancer cells, which hinders chemotherapy (35). 
When treatment is started, chemotherapeutic drugs are active in about 90% of patients 
with primary breast cancer, while they are active in only 50% of patients with metastatic 
breast cancer. However, after some time patients develop resistance to their treatments  
and the cancer will likely recur (36). “Patients with recurrent breast cancer usually die of 
their disease” (37). Recurrence happens in about 30% of patients that have early breast 
cancer (36). Survival after recurrence is based on several factors including where the 
recurrence is localized. Poor survival is associated with recurrence in soft tissue, bone 
and viscera (37). When relapse occurs, the resulting cancer is often more drug resistant 
(36). Therefore, it is imperative to explore the mechanisms of relapse in order to identify 
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targets, which may be used in the clinical setting to treat breast cancer. The statistics for 
relapse and survival will be given for each subtype of breast cancer below. 
 
Breast Cancer Classification 
The conventional classification of breast cancer includes early breast cancer, 
which accounts for about 85% of cases, locally advanced cancer (10%), and metastatic 
breast cancer (5%). Locally advanced cancer includes inflammatory breast cancer, a 
rare type of cancer (~3%) which will be discussed in detail later (reviewed in (38)). 
Breast cancer can also be classified by histology. An example of histological 
characterization includes either ductal or lobular carcinoma. Ductal carcinoma is 
characterized by formation of glandular structures while lobular carcinoma is more 
invasive and infiltrates regions beyond the basement membrane. Yet another 
classification identifies breast cancers based of genetic mutations. The most common 
breast cancer germline mutation is in BRCA (breast cancer susceptibility gene) -1 and -
2. Finally, molecular classification includes the steroid receptors found on breast cancer 
cells or the amplification of proto-oncogenes such has HER2/neu, as well as, the  
expression of genes associated with luminal-like, or basal-like cells. This classification is 
based on a genomic-proteomic approach that was pioneered by the group of Perou and 
colleagues (6).  
  
Initially, the authors developed an intrinsic gene set which was based on paired 
samples of tumors. Tumor samples were obtained before and after 42 patients 
underwent a 15-week treatment with doxorubicin (a chemotherapeutic agent). These two 
samples were called paired sets. All samples were compared using a microarray with 
approximately 8,000 genes. They noticed that the two samples obtained for each tumor 
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clustered together. This indicated that there were high levels of heterogeneity among 
different tumors. A set of genes was chosen based the expression patterns of genes that 
varied among different tumors as compared to the paired sets (39). 
 
 The molecular classifications were defined by microarray studies using 78 breast 
carcinomas and a set of 456 cDNAs, which were chosen from the intrinsic gene set (6). 
Based on their analysis Sorlie et al. defined five different types of gene-expression 
based molecular classes including, luminal-like A, B/C, basal-like, normal-like and 
HER2-positive (6). Recently, a new molecular subtype of breast cancer has been 
identified which involves expression of claudins (40). Claudins are proteins that form the 
tight junctions between adjacent cells and are responsible for blocking the diffusion of 
solutes between cells as well as maintaining apical and basolateral membrane domains 
(reviewed in (41)). Aberrant expression of claudins has been associated with a variety of 
diseases including metastasis in cancer (41). These different types of cancer will be 
discussed in detail below along with their ER status, possible treatments and survival 
statistics.  
 
Molecular Classification of Breast Cancer 
Luminal-like Breast Cancer 
 Estrogen receptor and breast cancer 
 The luminal group is subdivided into luminal A, B and C groups. Luminal type A 
cancers are mainly ERα-positive as are some luminal B and C type cancers. The luminal 
group is identified by the expression of cytokeratin markers 8 and 18. Luminal A tumors 
also expressed high levels of estrogen-induced genes such as GATA3 and LIV1. 
Luminal B tumors have moderate expression of ERα, as well as, genes associated with 
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proliferation such as Ki67 and the proliferating cell nuclear antigen (PCNA). While the 
luminal C group has low levels of ERα, expression and high levels of genes associated 
with the basal subtype. Because the status of the ERα is important in determining 
treatment of breast cancer, its role in breast cancer will be discussed next.  
 
“Estrogen promotes cancer cell growth of the breast and uterus” (15). ERα is 
found in 50-80% of tumors. The presence of ERα implies lower proliferation rates and 
increased rates of tumor differentiation. If ERα-positive cancer is treated in the earlier 
stages, there is a lower rate of recurrence, but if it has progressed, there is a higher rate 
of recurrence. The current hypothesis on how estrogens contribute to breast cancer 
development states that they induce estrogen-regulated proteins that act as growth 
factors (reviewed in (22)). The presence or absence of ERα drives the selection of 
appropriate therapeutics. For ERα-positive patients, endocrine therapies are commonly 
used. Tamoxifen is one of a group of agents known as selective estrogen receptor 
modulators (SERMS) and is a triphenyl ethylene derivative that blocks ERα activation. 
Tamoxifen binds to the ligand-binding domain in ERα, alters receptor conformation and 
prevents DNA binding and transcriptional activation (reviewed in (42)). More specifically, 
when tamoxifen binds to the ligand-binding domain, it causes helix 12 of ERα to obscure 
the ligand-binding domain so that co-activators cannot bind to this region (reviewed in 
(15)). While tamoxifen acts like an anti-estrogen in breast tissue, it acts as an estrogen 
in other tissues, such as the uterus, bone and brain. This is problematic because 
treatment of breast cancer with tamoxifen causes abnormal cell proliferation in the 
uterus potentially leading to endometrial cancer. In contrast, Fulvestrant is a pure anti-
estrogen. Fulvestrant binds to ERα preventing proper folding, which targets the receptor 
for degradation by the proteosome (reviewed in (42)).  
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Another class of drugs, aromatase inhibitors, are also useful for treatment of 
ERα-positive breast cancers. Aromatase is a cytochrome P-450 enzyme that is found in 
normal breast and breast cancer tissue among others. Its main function is to produce 
estrogens in the ovary from substrates such as testosterone or cholesterol. Non-
steroidal drugs, including letrozole and anastrozole, function by blocking the aromatase 
enzyme, which is required for the formation of estrogen (reviewed in (43)). They bind to 
the heme iron in cytochrome P-450 via their nitrogen atom and prevent steroidal 
hydroxylation. Both letrozole and anastrozole have shown promising results in treating 
breast cancer in post-menopausal women, and in some studies, they have been shown 
to be more effective than tamoxifen (reviewed in (44)). Currently, letrozole is the 
standard of care for ERα-positive breast cancer. Table 1 summarizes some of the 
hormonal therapies that are used to treat breast cancer. 
  
Estrogen receptor negative breast cancer and treatment 
In the case of ERα-negative cancer such as some of the cancers in the luminal B 
and C group (as well as basal cancers discussed below), endocrine therapies cannot be 
used. Therefore, chemotherapeutic agents need to be used. Chemotherapeutic agents 
can be classified into several groups: taxanes, vinca alkaloids, alkylating agents, 
anthracyclines, antimetabolites, as well as ATP competitive inhibitors and monoclonal 
antibodies. Taxanes are a group of drugs that work by binding to sites of tubulin dimers 
and stabilizing microtubules thereby preventing mitosis. As an example, Paclitaxel, 
works by stabilizing microtubules, preventing cells from passing through the G2/M phase 
of the cell cycle (45). Vinca alkaloids are drugs that disrupt microtubule formation 
preventing cell division. Alkylating agents bind to DNA and form cross-links between 
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DNA strands, which prevents DNA replication. Anthracyclines act as topoisomerase II 
poisons and intercalate between DNA strands preventing DNA replication. Finally, 
antimetabolites prevent purine and pyrimidine synthesis (reviewed in (46)). Other agents 
such as monoclonal antibodies will target the specific receptor and prevent activation. 
ATP competitive inhibitors will prevent the binding of ATP to a receptor, which will 
prevent autophosphorylation and activation of the receptor. Table 1 summarizes different 
chemotherapeutic agents that are discussed in this dissertation along with their targets 
and the types of breast cancers that they are used to treat. In some cases, 
chemotherapeutics can be used to treat several different types of breast cancer even 
though they may be discussed under only one section in the text. Importantly, some  
taxanes and anthracyclines, such as Paclitaxel and doxorubicin, can also be used to 
treat ERα-positive and ERα-negative breast cancer if the disease has become more 
advanced (47). The table contains only representative treatments and is not 
comprehensive.  
 
 In terms of survival and outcome with respect to the different types of luminal 
breast cancer, luminal A cancers are usually less aggressive than luminal B and C. 
Relapse may also be higher in the luminal B or C group. Studies have shown that 
recurrence of ERα-positive tumors is usually to bone; whereas, ERα-negative cancers 
tend to recur at visceral sites. Disease free survival was also highest in the luminal A 
group (5). The luminal C group had the worst outcome within the luminal group. The 
reason may be that luminal C cancers express some genes associated with the basal-
like group (6). Whether cancers are ERα-positive or ERα-negative also has an impact on 
their survival after recurrence. For example, if an ERα-positive patient has visceral 
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recurrence, the median survival time is 16 months, but this is reduced to 10 months for 
patients with ERα-negative cancer (37).   
 
HER2-positive breast cancer  
HER2 overexpression (HER2-positive) is mainly found in basal type cancers. 
HER2 belongs to a family of receptor tyrosine kinases, which also includes HER1 
(epithelial growth factor receptor, EGFR), HER3 and HER4. HER3 is a kinase dead 
receptor and HER2 has no known ligand. Upon ligand binding, HER1, HER3 or HER4 
will either homo- or heterodimerize (with each other or HER2) leading to phosphorylation  
of a tyrosine within the receptor cytoplasmic domain, which leads downstream signaling 
(via MAPK for example). Downstream targets include those that control cell growth, 
differentiation, motility, and adhesion (reviewed in (48)). Interestingly, HER2 can 
homodimerize without a ligand since it is constitutively active (49). Amplification of the 
HER2 gene is evident in about 20% of breast cancer (50). This overexpression leads to 
activation of the phosphoinositol 3-kinase (PI3K) pathway, which prevents apoptosis, 
and when combined with a loss of p53, which occurs in 40% of breast cancers, 
uncontrolled proliferation may occur (51) (reviewed in (52)). The activation of HER2 
leads to secretion of matrix metalloproteases that promote cell invasion and metastasis 
(53). Matrix metalloproteinases degrade the basement membrane and allow cells to 
metastasize. More specifically, HER family members can interact with focal adhesion 
kinase, which activates the PI3K pathway (54). Then second messengers such as 
inositol-triphosphate, diacylglycerol and calcium are recruited and reorganization of the 
actin cytoskeleton occurs which leads to tumor cell migration (55). 
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 The most common therapeutic agent used to treat patients with HER2 
overexpression is a humanized monoclonal antibody called trastuzumab (Herceptin). 
One possible mechanism of action for trastuzumab for killing tumor cells involves 
antibody dependant cell cytotoxicity. Once the antibody binds to the HER2 receptor, 
natural killer cells can detect the Fc portion and are recruited to the cell in order to lyse it. 
Evidence has shown that FcRγ+/+ mice implanted with breast cancer cells then treated 
with trastuzumab resulted in 96% tumor reduction (56). However, when mice that had 
the FcRγ deleted (FcRγ-/-) were treated with trastuzumab they had only 50% tumor  
reduction (56). This implies that FcRγ is important in trastuzumab initiated cell death and 
implicates antibody-dependant cell cytotoxicity as being partially responsible for the 
death of these cells. Studies showed that trastuzumab given before or after standard 
chemotherapy was effective in patients with HER2 overexpression (57, 58). Similar 
results were seen in NIH3T3 cell lines with enforced HER2 expression, where 
trastuzumab resulted in downregulation of the HER2 receptor (59).  
 
Sorlie et al. did an analysis of patient survival, and relapse-free survival, and 
found that patients with the HER2-positive subtype had one of the shortest overall 
survival times among the five different breast cancer classifications (6). In addition, 
disease free survival was also much shorter compared to the luminal group (6). In one 
study addition of trastuzumab to standard chemotherapy resulted in a 52% reduction in 
recurrence and a 33% reduction in death (34).  
 
 
 
 
  15  
 
Basal-like Breast Cancer 
 Normal-like breast cancer 
Briefly, normal-like breast cancer is mainly ERα-positive and HER-2-negative 
(60). These cancers make up about 8% of all breast cancers and are quite aggressive 
(61). They also express high levels of the epithelial to mesenchymal transition (EMT) 
markers TWIST1 and Vimentin compared to normal breast tissue (61). Briefly, EMT is an 
important factor in normal development and tumor progression. It allows for epithelial 
cells, which are normally attached, to become mesenchymal cells so they can migrate 
(62). Normal-like breast tumors are characterized by genes expressed in adipose tissue 
and non-epithelial cells. They expressed higher levels of basal genes as opposed to 
luminal genes (6). In terms of prognosis, normal-like tumors had slightly worse prognosis 
than luminal A in patients without therapy and were responsive to endocrine therapies 
having a good prognosis (60).  
 
Basal-like breast cancer  
Basal tumors are derived from myoepithelial cells found near the basement 
membrane. Basal breast cancer occurs in about 15-25% of all breast cancer cases 
(reviewed in (63)). The basal-like group consists of tumors that express a basal set of 
genes including EGFR, CK-5, and -17 and genes in the proliferation cluster including 
Ki67 and PCNA.  
 
 Interestingly, there may be a link between basal-like cancers and BRCA-1 
deficiency. The BRCA-1 mutation is a germ-line mutation, which is common in families 
that are predisposed to breast cancer. BRCA-1 is involved in DNA damage response 
(64), X-chromosome inactivation (65), and transcriptional regulation (66). Importantly, 
  16  
 
BRCA-1 mutations impair homologous recombination. This may lead to double stranded 
break formation and activation of oncogenes. In wild-type cells, double stranded breaks 
are repaired by an enzyme called Poly(ADP-ribose) polymerase (PARP), which binds to 
single stranded breaks formed during base excision repair (reviewed in (67)). BRCA-1 
deficient tumors are closely related to basal cancers based on gene array studies (5).  
 
One possible treatment for basal tumors or BRCA-1 deficient tumors would be to 
inhibit PARP leading to DNA double stranded breaks that cannot be repaired by RAD51-
dependant homologous recombination, leading to cell cycle arrest, and apoptosis. 
Farmer et al. showed that using PARP-1 inhibitors would lead to specific killing of BRCA-
1/2 deficient tumors (68). Patients that lack BRCA-1/2 will have a single copy of the gene 
in normal tissue; however, the tumor will not have any copies leading to more DNA 
damage and increased PARP expression. The authors demonstrated that embryonic 
stem cells lacking BRCA-1 or -2 were highly sensitive to killing by PARP inhibitors 
compared to wild-type controls in clonogenic assays (68). 
  
  Other potential therapeutic targets for basal-like tumors include EGFR or c-Kit, a 
receptor tyrosine kinase, either of which can be highly expressed in basal cancer 
compared to normal tissue. c-Kit is responsible for growth and differentiation of cells and 
dysregulated c-Kit has been seen in breast cancer. Imatinib (Gleevac) is a tyrosine 
kinase inhibitor targeting c-Kit, as well as, the abnormal protein BCR-ABL found in 
chronic myeloid leukemia (69). Imatinib works as an ATP-competitive inhibitor, which 
prevents the autophosphorylation and activation of c-Kit (69, 70). Several clinical trials 
have been done with Gleevec in breast cancer. Patients with advanced or metastatic 
breast cancer that overexpressed c-Kit generally did not benefit from treatment with 
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Gleevec alone (71). Additionally, a phase II trial showed little benefit when Gleevec was 
combined with the chemotherapeutic capecitabine in metastatic breast cancer (72). 
Capecitabine is a drug which is converted to 5-fluorouracil that then binds to DNA and 
prevents tumor growth. 
  
Triple-negative breast cancer and claudin-low breast cancer. 
  A specific group of basal tumors called triple negative breast cancer lack ERα, 
PR and HER2 receptors. Basal-type and triple negative classifications should not be 
used interchangeably since some basal tumors do express low levels of ER, PR or 
HER2 (73). Triple-negative breast cancers are identified by cytokeratins 5/6. They are 
very aggressive and account for 10-15% of breast cancer cases (73). Triple negative 
breast cancers express higher levels of EGFR and c-Kit than non-malignant breast 
tissue; these can be used as potential targets. EGFR can be targeted by Cetuximab and 
Gefitinib while c-Kit can be targeted by Imatinib as discussed. Cetuximab is a humanized 
monoclonal antibody that binds to EGFR and inhibits activation. Currently, Cetuximab is 
in clinical trials looking at its effect on triple negative metastatic breast cancer (clinical 
trials.gov. NCT00463788). Gefitinib, on the other hand, will block the ATP binding site on 
EGFR preventing its activation. The MAPK and protein kinase B (PKB/Akt) are also 
potential therapeutic targets in triple negative breast cancer (reviewed in (73)).  
 
Recently, a subset of triple negative breast cancer cells has been identified 
bearing a claudin-low phenotype (40). Metaplastic breast cancers, which are a subset of 
triple negative breast cancers, are especially difficult to treat. They make up about 1% of 
all breast cancer cases (74). A successful treatment regimen for these cancers has not 
been established. Standard chemotherapy similar to basal-like or triple negative breast 
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cancer has been used since they express markers associated with basal breast cancer 
including EGFR and CK-5/6, but these cancers are usually chemoresistant (75). This led 
to further analysis of these cancers using a genomic-proteomic approach, which showed 
they were related to a group of cancers characterized by a claudin-low phenotype.  
These cancers had a loss of specific genes associated with cell-cell adhesion, as well 
as, markers associated with EMT such as TWIST1 and snail homolog 2 (SNAI2/SLUG). 
Furthermore, the PI3K/AKT pathway was highly activated compared to non-cancerous 
tissue (74). This activation is not common in basal-type cancers; therefore, targeting this 
pathway may be useful in treating these rare cancers (75). 
  
Basal tumors are particularly aggressive, and women with basal-like breast 
cancer usually have poor relapse free survival (reviewed in (63)). Similar survival was 
observed in basal cancer as in HER2-positive breast cancer. Patients with triple negative 
breast cancer also have a poor outcome. High levels of metastasis to the bone (76) and 
the cerebellum (77) are common; furthermore, high levels of relapse are also widely 
found in triple negative breast cancer (78). In the USA, triple negative breast cancer 
seems to occur with higher incidence in premenopausal African-American women (79).  
 
Histological Classification of Breast Cancer 
Breast cancers can also be classified by their histology. These two types of 
classifications include ductal carcinoma in situ, which originates in the milk ducts, and 
lobular carcinoma in situ, which originates in the lobules (the milk producing glands) of 
the breast.  
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Ductal Carcinoma In Situ 
Ductal carcinoma in situ (DCIS) is a non-invasive breast cancer where mammary 
ductal epithelial cells become malignant. DCIS can be readily identified by 
mammography or as a palpable mass. In a study done between 1988 and 1996 DCIS 
was present in 23% of the 200 cases studied (80). On the cellular level, DCIS involves 
malignant ductal epithelial cells that are proliferating within the duct, but do not cross the 
basement membrane (80). The common treatments for DCIS include mastectomy or 
lumpectomy (excision of the mass) with or without radiation therapy. DCIS can be either 
ERα-positive or ERα-negative; however, most are ERα-positive. Tamoxifen has also 
been shown to be helpful in about 50% of the cases, which is strong rationale for using 
this agent in women with ERα-positive DCIS (6, 80). 
 
Lobular Carcinoma In Situ 
Lobular carcinoma in situ (LCIS) is found in approximately 5% of all breast 
malignancies. Pathologically, this cancer can be identified by proliferation of malignant 
cells within the terminal duct lobular apparatus (reviewed in (81)). This structure is found 
at the ends of terminal ducts, which differentiate into lobules. The role of these ducts is 
to provide milk to the nipple (2). LCIS tumor cells are highly ERα-positive with low levels 
of mutations. About 90% of LCIS cases occur in premenopausal women. While LCIS is 
relatively benign, it has the potential to become invasive. Treatments for patients can 
range from non-operative endocrine therapies (such as tamoxifen) to bilateral 
mastectomy in the case of invasive tumors (81).  
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Invasive Lobular and Ductal Carcinoma 
If left untreated both ductal and lobular carcinoma in situ can become invasive. 
Invasion is characterized by cancer cells moving beyond the basement membrane into 
the surrounding tissue. Pathologically these two carcinomas are distinct and will be 
described briefly below. 
 
Invasive ductal carcinoma occurs in about 47%-79% of women worldwide (82) 
and between 55%-72% of patients with invasive ductal carcinoma are ERα-positive.  
These cancers also have higher amplification of HER2 and p21 than invasive lobular 
carcinoma (83, 84). Cytologically, the most concerning type of infiltrating ductal 
carcinoma consists of a “comedo” subtype, which is characterized by a large number of 
necrotic cells that fill the mammary duct as well as microcalcifications in this region. 
 
Invasive lobular carcinoma occurs in about 3%-25% of women worldwide (82). 
Most (70%-92%) of these cancers are ERα-positive. This phenotype has been 
increasing rapidly especially in postmenopausal women and is difficult to diagnose (85). 
One reason is that invasive carcinoma is rarely characterized by a palpable mass. 
Morphologically, cells will infiltrate the stroma and surround the breast tissue (86). A 
study using microarray analysis comparing invasive ductal carcinoma and invasive 
lobular carcinoma showed that genes associated with cell adhesion/motility, fatty acid 
transport, and metabolism, as well as, genes associated with immune/defense response 
and electron transport were differentially regulated in the two types of cancer (85). 
Interestingly, invasive lobular carcinoma had a similar gene expression profile to normal 
like breast cancer (4-6). Since both types of cancer are positive for ERα, they may be 
treated with endocrine therapies (87).     
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Conventional Classification of Breast Cancer 
 
Inflammatory Breast Cancer 
Inflammatory breast cancer is characterized by rapid progression and a poor outcome 
(88). The name "inflammatory" breast cancer is misleading. The term comes from the 
reddened appearance of the breast, similar to what would be seen in an inflammatory 
response to infection, but here the reddened skin is actually caused by plugging of the 
lymphatics of the upper dermis with cancer cells. This type of breast cancer is rare and 
accounts for only 1-3% of breast cancers (89). It is a very aggressive disease, and 
surgery and radiation have little effect. About 62% of patients with inflammatory breast 
cancer have ERα-negative phenotype (90). Metastases occur in about 10-36% of cases 
at the time of diagnosis (88, 91, 92). However, if left untreated 90% of patients with 
inflammatory breast cancer may die within one year after diagnosis (93). Different 
combination chemotherapies have been used to treat these patients. Lopez summarizes 
various treatments including mastectomy, radiotherapy, hormonal therapy, Vincristine, 
Methotrexate and Vinblastine. The 5-year overall survival for these different treatments 
is given as 46% using a combination therapeutic approach (88).  
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Cancer Stem Cells 
The History of Cancer Stem Cells 
The idea of cancer stem cells (CSCs) dates back to the 1950s when studies 
identified stem cells in germinal cancer (teratocarcinomas). The first studies done by 
Table 1: Summary of some endocrine therapies and chemotherapeutic agents 
used to treat breast cancer. ER= estrogen receptor, TN=triple negative, SERM = 
selective estrogen receptor modulator, EGFR = epithelial growth factor receptor, 
ATP comp. inhibitor = ATP competitive inhibitor 
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Greene showed that embryonic tissue or cancerous tissue would grow in immune 
privileged sites of mice while normal tissue would not (106). Dilution studies showed that 
the tumor initiating cells were found at a frequency of 1:30-1:1000. These results were 
similar to the number of cells that survived chemotherapy. Later Salman et al. found that 
in adenocarcinoma the ratio of tumor initiating cells to normal tumor cells was between 
1:1000- 1:100,000 (107). These cells could also form colonies in soft agar. Therefore, a 
foundation was set for many studies to come in the future on this topic (108).  
 
Theories of Cancer Formation 
 Before discussing the theories of cancer formation, it is important to report the 
types of mutations that would need to occur in a normal cell in order to become a cancer 
cell. These are often called the hallmarks of cancer and include mechanisms for the cell 
to evade apoptosis, to be self-sufficient in growth signals, to have limitless replicative 
potential, to be able to sustain angiogenesis and to be able to metastasize (109). These 
qualities need to be achieved in order for a cell to become cancerous. Usually, this 
occurs by deregulation of signaling pathways associated with normal cell function (109). 
 
Stochastic theory  
In the traditional model of carcinogenesis (often called the stochastic model), 
cancer occurs through a series of mutations caused by environmental or other factors 
that lead to genetic instability (110). This model states that mutations can occur in any 
cell, which will become transformed given that the appropriate mutations occur 
(reviewed in (111)). This model also states that a tumor is relatively homogeneous and 
that the pathways that lead to tumorigenesis are active in all tumor cells. Therefore, it 
would be difficult to find the exact cell from which a particular tumor originated because 
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virtually any cell within the appropriate lineage would have an equal probability of 
initiating that tumor.  
 
 Another model that is related to the stochastic model is the clonal evolution 
model. In this model, certain cells are given a survival advantage (because of 
mutations). These cells will be selected for and survive while normal cells will die. The 
mutated cells produce daughter cells leading to tumor growth. Tumor heterogeneity is 
due to aberrant differentiation, impact from epigenetic variation, and alterations due to 
the microenvironment.  
 
However, the stochastic model cannot explain some other aspects of tumors. 
First, numerous mutations are required to fully transform a cell, and it would take longer 
than the normal life span of a typical cell to acquire these mutations. Second, if tumors 
are derived from a single transformed cell, cancers would be fairly homogenous. Yet, it 
is well recognized that breast tumors are highly heterogenous. Third, cancers can recur 
despite treatment that appears to completely eliminate the tumor. This suggests that 
highly tumorigenic cancer cells are able to evade death caused by chemotherapy and 
radiation. These cells can later proliferate to cause recurrent or metastatic disease. As 
discussed below, the cancer stem cell theory appears to address these issues.  
 
The cancer stem cell theory  
Another model for tumor development is the cancer stem cell (CSC) model (also 
known as the hierarchical model). This model states that a subset of tumor cells, termed 
CSCs, may be ultimately responsible for cancer initiation and recurrence (reviewed in 
(112)). These cells can self-renew and differentiate, which is thought to be responsible 
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for tumor heterogeneity. Self-renewal is defined as the ability to produce an exact copy 
of a cell, which has the same ability to proliferate, differentiate and expand as the 
parental cell (113). Progenitor cells or fully differentiated cells in the tumor do not have 
this capability. The CSCs possess several other characteristics of normal tissue stem 
cells including indefinite proliferation, slow replication, and production of daughter cells 
that undergo multilineage differentiation. The daughter cells make up the bulk of the 
tumor and are non-tumorigenic, while the CSCs are tumorigenic and make up a small 
proportion of the tumor, though this is controversial and will be discussed in detail in a 
separate section. CSCs are also capable of unlimited proliferation. It is hypothesized that 
CSCs are able to evade killing by traditional therapeutic approaches by utilizing some of 
the same properties that protect normal stem cells from these agents. For example, 
current therapies often target rapidly proliferating cells; however, CSCs, like normal stem 
cells, are believed to divide slowly and can even enter quiescence. Furthermore, CSCs 
and normal stem cells express higher levels of anti-apoptotic proteins than non-stem 
cells and express higher levels of multidrug resistant transporters called ATP Binding 
Cassette (ABC) transporters than non-stem cells, which effectively efflux toxins from the 
cell (114). Together, these characteristics may protect the CSCs from traditional 
therapies allowing them to remain unharmed after destruction of the bulk tumor cells and 
capable of causing relapse or metastases.  
  
It is clear that CSC possess qualities that may make them more suitable for 
transformation. First, they are long-lived, which gives them time to acquire mutations, 
and secondly, they may need to acquire fewer mutations in order to become cancerous. 
For example, stem cells have the ability to migrate (a quality necessary for metastasis), 
and they are resistant to apoptotic signals and have limitless proliferation potential. 
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These cells have already fulfilled some of the hallmarks of cancer without acquiring any 
mutations. Therefore, they would need a smaller number of mutations in order for 
transformation to occur and since they are long-lived; they have the time to acquire 
them.  
 
The CSC model may also explain why tumors are heterogeneous. Dontu et al. 
proposed a theory where CSCs can develop from ERα-negative stem cells or ERα-
positive progenitor cells. An ERα-negative stem cell can become mutated, and lead to 
the formation of an ERα-negative CSC (33). This CSC may self-renew producing 
additional ERα-negative CSCs or differentiate into ERα-negative cancer cells. These 
types of cancers are poorly differentiated and usually found in the basal group when 
characterized by molecular profiling. Mutations can also occur in the progenitor cells 
leading to the formation of either ERα-positive or negative CSCs. In this case tumors 
would contain both ERα-positive and ERα-negative cancer cells. This theory can help 
explain problems with treatments. These tumors are likely to recur if treated with anti-
estrogens, for example, because the ERα-negative stem cell would not be affected by 
these treatments and would produce other ERα-positive or negative cancer cells. ERα-
positive cells can also arise from ERα-positive progenitor cells that have re-acquired 
self-renewal and mutated into CSCs. ERα-positive tumors could therefore be derived 
from either an ERα-negative CSC where the daughter cells differentiate down an ERα-
positive pathway or from an ERα-positive CSC. These types of tumors are well-
differentiated and may respond well to anti-estrogen therapies (33).  
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The Origin of CSCs.  
CSCs may arise from stem cells, progenitor cells or somatic cells that 
accumulate genetic mutations that result in deregulated self-renewal and production of 
daughter cells that undergo aberrant differentiation (115). Several lines of evidence 
support each of these possibilities. Normal tissue stem cells are already capable of 
indefinite self-renewal and can give rise to more differentiated progenitors making them 
an obvious possible source of CSCs. They are also long-lived and would be capable of 
accumulating the serial mutations required for transformation over the lifetime of the cell. 
Finally, CSCs tend to express markers associated with normal tissue stem cells such as 
CD133, nestin, c-kit, sox2, oct4 and musashi-1 (116-119).  
 
 Alternatively, CSCs may be derived from progenitor cells. Although relatively 
immature, progenitor cells have lost the ability to self-renew and would need to re-
acquire this ability to generate a CSC. Recent evidence indicates this may be possible, 
at least in leukemic cells, where the introduction of oncogenic fusion gene products into 
hematopoietic progenitor cells resulted in acute myeloid leukemia in animal models. 
Cozzio et al. found that expression of the MLL-ENL fusion gene product in hematopoietic 
progenitor cells resulted in leukemia, albeit with less efficiency than when expressed in  
true hematopoietic stem cells (120). Similar results were also found with the MOZ-TIF2 
fusion gene product (121). However, these studies were performed in a mouse model. 
Murine cells are known to be more readily transformed than human cells. Therefore, it is 
unclear if similar results are possible using progenitor cells from the more complex 
human system.  
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 Finally, somatic cells may undergo mutations resulting in re-programming to a 
multipotent stem cell phenotype. Recent studies indicate that cells called induced 
pluripotent stem cells could be obtained from normal fibroblasts by transduction with 
specific factors (Oct3/4, sox2, Klf4, and c-Myc). When these factors were added to 
differentiated fibroblasts the resulting cells were very similar to human embryonic stem 
cell in morphology, cell surface markers, proliferation and telomerase activity (122). 
Similarly, Yu et al. showed that expression of oct4, sox2, nanog, and LIN28 in human 
dermal fibroblasts converts them into pluripotent cells with a phenotype virtually 
indistinguishable from embryonic stem cells (123). Although experimental evidence 
indicates that CSCs may be derived from any of these cells (stem, progenitor or fully 
differentiated somatic cells), it is currently unknown, which is the origin of breast CSCs. 
Indeed, it is possible that breast CSCs are derived from all three types of cells 
depending upon the genetic and epigenetic characteristics of an individual tumor. These 
possibilities are summarized in figure 3.  
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The Stem Cell Niche 
 As mentioned above stem cells have the ability to self-renew, differentiate, or 
remain quiescent. The signals that drive these decisions come from the surrounding 
microenvironment referred to as the stem cell niche. The niche is made up of a 
specialized group of cells that interact with the stem cell and are responsible for its 
maintenance. The niche is found in a specific location in normal tissues. For example, 
the skin stem cell niche is located in the hair follicle (124). It is unclear where the breast 
stem cell niche resides. Stem cells are physically attached to the niche by various 
adhesion proteins. Extrinsic signals will trigger the niche to cause the stem cells to 
differentiate. Until these signals are received, the stem cell will be maintained in a 
Figure 3: Simplified model of the role of stem cells in normal breast 
development and tumorigenesis. Under normal circumstances a 
mammary stem cell will self-renew to a stem cell or differentitate into 
luminal or myoepithelial cells. Mutations can occur at the stem cell,  
progenitor or somatic cell level, which would lead to a CSC. In the case of 
the progenitor and somatic cells, the ability to self-renew would need to be 
re-acquired. The mutated stem cell can differentiate into tumor cells.   
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quiescent state. A niche for the CSC has also been identified for several cancers. The 
niche is thought to maintain self-renewal and differentiation of the CSC, as well as, 
protect these cells from apoptotic agents (125). Neural stem cells occupy regions called 
“vascular niches” which are rich in blood vessels and lined by endothelial cells. 
Endothelial cells are thought to secrete factors that promote self-renewal and survival of 
CSCs (125). Interestingly, disruption of the niche may be one way of targeting CSCs, 
since this would cause differentiation of the CSCs. Calabrese et al. showed that after 
transplanting medulloblastoma cells in the presence or absence of endothelial cells 
resulted in tumors with up to 25 times higher levels of CSCs in the presence of 
endothelial cells than when they were absent (126). 
 
Identification and Isolation of Normal Stem Cells and CSCs in vitro  
The identification and isolation / enrichment of normal stem cells was a major 
advancement in the ability to test the cancer stem cell theory. Currently, four different 
methodologies have been successfully used: side population (SP) (127), sphere 
formation (128), cell surface markers (129, 130), and aldehyde dehydrogenase (ALDH) 
activity (131). It is important to note that these methodologies can identify / isolate either 
normal stem cells or CSCs from various tissues.  
 
Side population  
As stated earlier, stem cells and CSCs express high levels of multidrug resistant 
transporters (ABC transporters). These transporters can efflux different substrates 
including lipids, metabolites, and ions as well as a variety of drugs including 
chemotherapeutic drugs making cells resistant to treatment (132-134). Researchers 
have taken advantage of the fact that these transporters also efflux vital fluorescent 
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dyes, including Hoescht 33342 and DyeCycle Violet (135). Bulk cell populations can be 
loaded with dye, which is effluxed from the stem cells within the sample via the ABC 
transporters (136, 137). These cells become less fluorescent than the bulk cell 
population and can be readily identified on flow cytometry and collected through 
fluorescence-activated cell sorting (FACS). As the stem cells (or CSCs) are the small, 
less fluorescent population at the side of the majority of cells, they are termed the SP. To 
confirm identification of the SP, drugs that block ABC transporter activity, such as 
verapamil hydrochloride or reserpine, can be used to prevent efflux of the dye (127). 
Under these conditions, the stem cells / CSCs retain the dye and the SP will “disappear” 
as the cells remain fluorescent (since their efflux channels are blocked) and sort with the 
bulk cell population.  
 
Evidence has confirmed that SP cells are enriched for stem cells. Alvi et al. showed 
that the SP isolated from normal mammary tissue were undifferentiated, but could be 
prompted to differentiate into epithelial or myoepithelial cells in culture (136). Reverse 
transcriptase polymerase chain reaction (RT-PCR) analysis has confirmed increased 
expression of several ABC transporters in SP cells derived from normal breast tissue 
compared to non-SP (136). In addition, SP cells derived from the MCF7 breast cancer 
cell line were shown to be more tumorigenic than the non-SP (137). When 1,000 SP 
cells collected from the MCF7 cell line were injected into mammary fat pads of mice, 
tumors reproducibly formed, while injection of tens of thousands of non-SP cells could 
not produce a tumor (137).  
 
 Further evidence has specifically linked the ABCG2 (BCRP1) channel in 
conferring the SP phenotype in both hematopoietic progenitors derived from lung, as 
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well as, human embryonic kidney cells (HEK293) and bone marrow (30). In one study, 
SP cells were isolated from murine bone marrow using FACS. Elevated expression of 
ABCG2 in the SP compared to non-SP cells was confirmed by RT-PCR along with lower 
expression levels of other transporter proteins ABCC1 (MRP1), ABCC2 (MRP2), ABCC3 
(MRP3) and ABCC4 (MRP4) (30). Scharenberg et al. showed that the expression of the 
ABCG2 transporter was sufficient to confer the SP in hematopoietic stem cells (138).  
 
Mammosphere formation  
Maintenance of stem cells in an undifferentiated state in culture has only recently 
been possible due to the development of specialized non-adherent culture conditions. In 
work pioneered by Reynolds and Weiss, neural stem cells were grown as neurospheres 
where about 20% of sphere cells were able to self-renew (form spheres) and 
differentiate along multiple lineages (139, 140). Dontu and colleagues modified this 
system to successfully culture mammary stem cells and breast CSCs as 
mammospheres (128). Here, bulk cell populations from reduction mammoplasties 
(normal breast tissue) were plated on ultra-low adhesion tissue culture plates in serum 
free media supplemented with growth factors (EGF, bFGF), protein supplement B27, 
and heparin (128). To confirm the spheres were composed of stem and progenitor cells, 
mammospheres were immunostained for expression of markers associated with luminal 
(epithelial specific antigen (ESA), Muc-1, CK-18), myoepithelial (CD10, α-smooth muscle 
actin, α-integrin 6), and progenitor cells (CK-5, CK-14) (141). They observed that Muc-1, 
α-smooth muscle actin, and CK-18 were not found in mammospheres. CD10, CK-5 and 
α-integrin 6 were present in a few cells and ESA (50% of cells) and CK-14 (30% of cells) 
were randomly dispersed (128). They determined that each sphere was derived from a 
single mammary stem cell having the ability to self-renew and differentiate along any of 
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three mammary-related lineages: alveolar epithelial, luminal epithelial or myoepithelial. 
Each mammospheres was composed of 1-2 multipotent stem cells surrounded by 
bipotent and tripotent progenitor cells (128). Mammospheres were also shown to be 
more tumorigenic than bulk cultured cells. Grimshaw et al. showed that injecting only 
5,000 mammosphere cells derived from a breast cancer pleural effusion was sufficient to 
produce tumors in non-obese diabetic severe combined immune deficient (NOD/SCID) 
mice (142). Tumor formation was correlated with samples that could form large 
mammospheres (142).  
  
CD44+ CD24-/low ESA+ and CD133 markers  
 Another way of identifying breast CSCs is to examine expression of cell surface 
markers including CD44, CD24, and ESA. Cells derived from either xenograft tumors or 
breast cancer pleural effusion samples that have the CD44+ CD24-/low Lineage- ESA+ 
phenotype were shown to be more tumorigenic than cells expressing other combinations 
of CD44, CD24, and ESA (129). As few as 200 cells with the CD44+ CD24-/low Lineage- 
ESA+ phenotype isolated from primary breast cancers were required to reproducibly 
initiate tumor formation in mice (129). Furthermore, once tumors were established, the 
CD44+ CD24-/low Lineage- ESA+ cells could be re-isolated from the tumor and serially 
passaged into naïve animals indicating this population was capable of self-renewal 
(143).  
 
 In a study by Sheridan et al. the CD44+ CD24-/low was isolated from various breast 
cancer cell lines (MCF7, T47D, MDA-MB-231, MDA-MB-468, and SKBR3 among 
others). This phenotype was found in mainly basal/mesenchymal or myoepithelial cells 
but not luminal cells (144). These cells also contained certain genes associated with 
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metastasis such as interleukin-6, interleukin-8 and urokinase plasminogen activator. 
Different cell lines tested showed that the CD44+ CD24-/low phenotype was consistent 
with invasion. However, this phenotype was not responsible for homing and proliferation 
at the site of metastasis (144). Fillmore and Kuperwasser showed that the CD44+ CD24-
/low ESA+ phenotype derived from breast cancer cell lines correlated well with tumorigenic 
potential while the CD44+ CD24-/low phenotype did not. Breast cancer cell lines derived 
from luminal cells (such as MCF7 and SUM225) contained very low levels (<1%) of this 
phenotype while breast cancer cell lines derived from basal cells (MDA-MB-231,  
SUM1315 and SUM 159) contained higher levels (>1%). These cells were also shown to 
be more tumorigenic than CD44+ CD24-/low ESA– cells (145). In another study, no 
correlation was observed between tumorigenicity and the percentage of CD44+ CD24low/- 
cells in pleural effusions from metastatic breast cancer patients (142). 
 
 In a clinical study, breast cancer patients on chemotherapy (Docetaxel, or 
Doxorubicin and Cyclophosphamide) were monitored for the presence of the CD44+ 
CD24-/low phenotype in biopsy samples taken before, during and after their treatment. 
The results showed that tumors had much higher levels of CD44+ CD24-/low after 
chemotherapy than before treatment (146). This indicated the cells were resistant to 
chemotherapeutic agents, which killed off the majority of the bulk tumor cells leaving the 
putative CSC intact. The authors also showed an increase in mammosphere efficiency 
when the CD44+ CD24-/low fraction was grown as mammospheres (146).  
 
 The CD44+ CD24-/low population was also shown to be more resistant to radiation 
therapy. Phillips et al. found that MCF7 and MDA-MB-231 cells grown as 
mammospheres (which contained elevated levels of CD44+ CD24-/low compared to cells 
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grown in a monolayer) had elevated levels of Notch-1 after irradiation (147). 
Mammospheres were also much more resistant to radiation than cells grown in a 
monolayer. Additionally, the CD44+ CD24-/low phenotype increased significantly in the 
mammosphere population after treatment with radiation, however, that was not the case 
for the adherent population (147). 
 
Finally, using a genomics-proteomics approach the gene expression patterns of 
CD44+CD24low/- and the different molecular classifications of breast cancer were 
identified. It was found that metaplastic breast cancer (claudin-low) had a high ratio of 
the CD44+/CD24low/- phenotype. In addition, the CD44+ CD24low/- genomic profile 
correlated with the metaplastic breast cancer and claudin-low profiles (75). This 
indicates that these cancers express high levels of genes associated with the stem-like 
phenotype.  
 
More recently, CD133, a known marker of hematopoietic stem cells has been 
shown to be co-expressed with high levels of stem cell-regulatory genes in breast cancer 
stem-like cells (130, 148). It should be noted that the CD133 marker does not only 
identify breast CSCs but also glioma, brain, and prostate CSCs (149, 150). Wright et al. 
used cell lines derived from human tumor xenografts to test the presence of CD44+ 
CD24-/low and CD133-positive. They found that in cell lines derived from a tumor that had 
low levels of CD44+ CD24-/low contained higher levels of CD133-positive cells (between 2 
to 6%) (130). CD133-positive cells were also more tumorigenic than CD133-negative 
cells requiring only 50-100 cells to initiate a tumor in NOD/SCID mice. Although fewer 
reports have utilized CD133 as a marker for breast CSCs, it appears this marker may be 
useful, particularly in cases where CD44, CD24 staining has not been helpful.  
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Aldehyde dehydrogenase-1 (ALDH) activity 
ALDH, an enzyme that oxidizes intracellular aldehydes, has been described as a 
putative marker for normal stem cells and CSCs (131, 151-153). Based on sequence 
analysis, three classes of mammalian ALDHs have been identified: ALDH-1, -2, and -3. 
Classes 1 and 3 contain ALDH isoforms that are both constitutively expressed and 
inducible. Class 2 isoforms are constitutively expressed in the mitochondria. Each class 
of ALDH appears to oxidize a variety of different substrates. Of importance to our work, 
the Class 1 isoform A1 (ALDH1A1) has been identified as highly expressed in embryonal 
tissue as well as in adult stem cells (154).  
 
ALDH appears to be responsible for oxidizing retinol to retinoic acid, which is 
important in early stem cell differentiation (155), and it may also be involved in 
chemoresistance (156). High levels of ALDH-1 were found in metastatic breast cancers 
and shown to cause resistance to the chemotherapeutic agent cyclophosphamide (157). 
High ALDH-1 activity has been associated with murine hematopoietic stem cells from 
bone marrow or neural stem cells (158, 159). Cells containing elevated levels of ALDH-1 
have also been identified in leukemia, multiple myeloma, and breast tumors (153). 
Ginestier et al. identified and isolated breast CSCs using the Aldefluor assay where the 
ALDH-1 enzyme converts the substrate BODIPY-aminoacetaldehyde into the fluorescent 
product BODIPY-aminoacetate which can then be analyzed by flow cytometry (131). 
Stem-like cells become highly fluorescent due to increased ALDH-1 activity and are 
readily detectable by flow cytometry. Ginestier et al. showed that only the Aldefluor-
positive, but not the Aldefluor-negative cell population, could form mammospheres in 
culture and tumors in mice, even when injected at low cell numbers. In fact, using 
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Aldefluor-positive cells that were also CD44+ CD24low/- Lineage-, they found that as few 
as 20 cells were able to generate a tumor. In contrast, Aldefluor-negative cells that were 
CD44+ CD24- Lineage- were unable to form tumors when 50,000 cells were implanted 
(131). 
 
The Cancer Stem Cell hypothesis and multidrug resistance 
The CSC hypothesis may explain why resistance occurs in breast cancer. Two 
types of resistance exist: inherent and acquired. Stem-cells have inherent resistance as 
they possess channels that will allow them to efflux various toxins. As stem-cells divide 
they produce progenitor cells which are sensitive to various drugs. However, in 
aggressive types of cancer these progenitor cells or differentiated may acquire 
resistance via gene amplification or rearrangement, to various drugs and be given a 
survival advantage leading to acquired resistance. In this case, certain therapies may 
become ineffective after prolonged treatment (160).   
 
The Cancer Stem Cell Hypothesis Controversy  
The CSC hypothesis remains controversial. First, some investigators argue that 
the hypothesis itself is incorrect and maintain that cancer follows the stochastic theory. 
This argument is based on the idea that every cancer cell is equally tumorigenic. When 
human tumor cells are injected into mice, even in orthotopic models, the cells are 
required to grow in a foreign and potentially adverse environment. Some tumor cells may 
simple be unable to grow under these conditions. For example, the CD44+CD24low/- 
subset of human breast cancer cells may simple be better able to survive in the murine 
mammary fat pad than their CD44+CD24+ counterparts. This viewpoint was supported by 
studies by Kelly et al. who used primary murine lymphoma cells derived from E-myc 
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transgenic mice and implanted them into the same strain of mouse (161). They found 
that as few as 10 lymphoma cells could form tumors under these conditions. Moreover, 
they found that lymphoma cells with a murine stem cell phenotype (Sca+ AA4.1High) or a 
non-stem phenotype (Sca+ AA4.1low) were equally as effective at initiating lymphoma in 
mice. Supporters of the CSC theory, however, argue that the Eu-myc transgenic model 
system used in these experiments may have influenced the results. These mice 
overexpressed the oncogene c-Myc, and the model was chosen as a means to 
accelerate the process of tumorigenesis. However, c-Myc has been identified as one of 
the key genes involved in reverting fully differentiated fibroblast into cells with a stem 
phenotype. Thus, overexpression of Myc in the tumor cells may have played a role in 
dedifferentiation of the cells toward a stem-like phenotype giving them a growth 
advantage. 
 
Another CSC controversy is whether or not the CSC must be a rare subset of the 
tumor cells. The original definitions of CSCs stated that they were less than 1% of the 
total tumor cell population. Yet, several studies have found cells with the stem 
phenotype are actually quite common in some tumors or cancer cell lines. For example, 
Al Hajj et al showed that between 11 and 35% of breast cancer cells in pleural effusions 
possessed the CD44+ CD24low/- phenotype. However, breast cancer pleural effusions 
represent aggressive, metastatic disease, and it has been proposed that more 
advanced, aggressive cancers likely contain a higher proportion of stem-like cells.  
 
Although not strictly related to the CSC hypothesis, the utility of SP in stem cell 
studies is also controversial. As stated earlier, the SP is identified as the subset of cells 
that do not maintain a vital fluorescent dye, such as Hoechst 33324. As stem cells can 
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actively efflux these dyes via ABC transporters, it was hypothesized that they could be 
enriched by collecting the non-fluorescent subset of Hoechst-stained cells on flow 
cytometery. Indeed, SP cells from mammary tissue are enriched for stem cell markers, 
lack differentiation markers and are more tumorigenic in animal models than non-SP 
cells (136, 137, 162). While some investigators have reported that  the normal mammary 
stem cells that can generate mammary glands in mice are not found in the SP  (32) 
other investigators have found that the SP proliferates rapidly when the ducts are being 
formed, but remains quiescent in the adult mouse (29) . Furthermore, when the SP is 
transplanted the progeny can form ductal and alveolar structures (29). This suggests 
that the SP contains the stem/progenitor cell population. In addition, concerns have been 
raised regarding the toxicity of the dyes in cells that do not exclude it, as this may alter 
interpretation of functional assays performed with SP and non-SP cells. As SP analysis 
was one of the first methods for identifying stem-like cells, it is still widely utilized. 
However, the development of other techniques that do not have these problems have 
led many investigators away from this technique. 
 
As self-renewal and the capacity to differentiate along multiple lineages are the 
hallmarks of stem cells, assays capable of measuring these factors are the best assays 
for CSC studies. The gold standard for demonstrating CSCs is serial transplantation in 
an animal model. Here, the CSC subset is injected into the animal, a tumor is formed  
(which can be evaluated for heterogeneity), and the CSCs re-isolated and injected into a 
naive animal (showing self-renewal). As these assays can take long periods of time, in 
vitro assays such as sphere formation and colony formation assays have become 
mainstays in the field.  
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The Notch Signaling Pathway  
As mentioned above one way of eliminating CSCs would be to target pathways 
that are dysregulated in CSCs. The Notch pathway is one such pathway that is 
dysregulated in both CSCs and breast cancer.  
 
The Structure of Notch 
The Notch receptor was first described in Drosophila by Thomas Hunt Morgan. 
He noticed a unique notched phenotype in the wings of Drosophila (163). Later it was 
discovered that this phenotype was due to a haploinsufficiency of the Notch gene. The 
Notch gene in Drosophila was cloned by Artavanis-Tsakonas and Young in 1985 (164, 
165). In mammals there are four Notch receptors (Notch-1,-2,-3,-4) and five Notch 
ligands (Delta-like (Dll) -1, -3, -4, and Jagged (Jag)-1,-2) (reviewed in (166)). The ligands 
are homologous to the Drosophila ligands Delta and Serrate.  
 
 The Notch receptor is a heterodimer and consists of an extracellular portion and 
a transmembrane region (163). The extracellular portion is composed of epidermal 
growth factor (EGF)-like repeats, which are involved in ligand binding and three 
cysteine-rich Notch/LIN12 repeats (LN) that prevent Notch activation in the absence of 
ligand binding. The intracellular portion of Notch contains a RAM domain, six ankyrin 
repeats (ANK), two nuclear localization signals (NLS), a transcription transactivation 
domain (TAD) and a PEST (proline, glutamate, serine, and threonine) sequence, which 
is important in mediating Notch degradation. The different Notch receptors have a very 
similar structure but vary in the number of EGF-repeats. Notch-1 and Notch-2 contain 36 
EGF repeats while Notch-3 has 34 EGF repeats and Notch-4 only 29 EGF repeats. 
Additionally, Notch-1 contains a strong TAD region while Notch-2 contains a weak TAD, 
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and Notch-3 and Notch-4 do not have any TAD regions. The Dll and Jag ligands also 
contain EGF-like repeats and a DSL region (Delta, Serrate and LAG-2), which will 
interact with Notch at the amino-terminal end. Figure 4 summarizes the structure of the 
different Notch receptors and ligands.  
 
 
 
 
 
 
 
 
Notch signaling  
The Notch signaling pathway is an evolutionarily conserved signal transduction 
mechanism by which neighboring cells can communicate with one another. The 
precursor to the Notch receptor is formed in the endoplasmic reticulum then is 
transported to the Golgi apparatus where it is cleaved by a furin protease (167). This 
Figure 4: A summary of the structure of the four Notch receptors. Each receptor 
consists of an intracellular and extracellular portion. The extracellular region 
contains EGF repeats that interact with the EGF-like repeats of the Dll and Jag 
ligands. EGF= epidermal growth factor, LN = cysteine-rich Notch/LIN12 repeats 
ANK= ankyrin repeats, TAD=transactivation domain, NLS = nuclear localization 
signal, PEST = proline, glutamate, serine and threonine, DSL = Delta, Serrate, 
Lag1, Dll = Delta-like, Jag = Jagged, CR= cysteine rich region. Modified from 
Radtke and Raj (163).  
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cleavage produces the extracellular domain and the transmembrane domain. The two 
are associated in a non-covalent calcium dependant interaction. The extracellular 
domain binds the ligand and the intracellular domain is required for further signaling after 
ligand binding. The Notch protein is transported to the membrane. Ligand-receptor 
interaction triggers two successive proteolytic cleavages of the receptor; first by ADAM 
10/17 (a disintegrin and metalloprotease) and then by the γ-secretase complex. After the  
first cleavage the extracellular portion is endocytosed into the ligand bearing cell (168). 
The second cleavage releases the intracellular portion of the receptor (NIC), which is 
called the active form of Notch. NIC translocates to the nucleus where it binds to the CSL 
(CBF-1/RBP-Jκ (mammalian), Suppressor of Hairless (Drosophila), Lag-1, 
(Caenorhabditis elegans)) transcription factor, via its RAM23 domain and displaces the 
co-repressor complex (including silencing mediator of retinoid and thyroid hormone 
receptors (SMRT), histone deacetylase (HDAC-1), and Ski-interacting protein, (SKIP), 
CBF-1 interacting corepressor (CIR), and SMRT/HDAC-1 associated repressor protein 
(SHARP)) (169). RAM and TAD are involved in the binding of the activated form of 
Notch to CBF-1. Ankyrin repeats further stabilize the interaction between NIC, CBF-1 and 
the DNA. A co-activator complex consisting of mastermind-like 1 (MAML1), histone 
acetyltransferases (p300, PCAF/GCN5 for example) is then recruited leading to 
transcriptional activation and expression of various target genes including two families of 
transcription factors, hairy enhancer of split (Hes), and hairy/enhancer of split related 
with YRPW motif (Hey) (170-173). The Hes and Hey family are a group of basic helix-
loop-helix transcription factors that are involved in repressing expression of various 
activators of cellular differentiation. Studies have demonstrated that at least Hes-1, Hey-
1, and Hey-2 are primary targets of Notch activation (170-173). The Notch pathway is 
summarized in Figure 5. There are many other Notch targets including p21Cip/Waf, cyclin 
  43  
 
D1, cyclin A, and NF-κB (reviewed in (174)). Some negative regulators of Notch include 
Numb, which causes endocytosis of Notch followed by its degradation in the 
proteosome. Notch can also be degraded by one of several E3 ubiquitin ligases 
including Deltex (175). It is important to note that Notch activation of downstream target 
genes is context dependant, that is, different Notch targets can be upregulated 
depending on the cell type, the Notch receptor and ligand involved in signaling and the 
density of the receptors and ligands. 
 
 Notch can also signal via a non-canonical signaling pathway, which is 
independent of CBF-1. Some targets of Notch signaling that are modulated 
independently of CBF-1 include β-catenin, hypoxia inducible factor-1α and Deltex. 
Interestingly, Deltex is a downstream target of Notch, which then binds to Notch along 
with β-arrestin and leads to its ubiquitination and degradation. 
 
 
 
 
 
 
 
 
 
 
 
  44  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notch in Breast Cancer 
Notch acts as an oncogene in breast cancer. It may play a role in tumorigenesis 
by increasing proliferation or preventing differentiation of cells (reviewed in (174)). 
Several oncogenic targets of Notch include cyclins A, D1, and D3, HER2, and NF-κB 
(reviewed in (174)). Several studies have been done in order to elucidate the roles of 
Notch in cancer. The first studies examined mice with mammary tumors caused by the 
murine mammary tumor virus (MMTV). In 20% of tumors, the MMTV genome integrated 
into the Notch-4 gene causing overexpression of a truncated Notch-4. The enhancer 
sequences in the viral long terminal repeats promoted transcription of the intracellular 
Figure 5: Simplified diagram of canonical Notch signaling. The Notch 
receptor is synthesized as a precursor protein that is cleaved in the Golgi 
apparatus by a furin-like protease creating the extracellular and 
transmembrane / intracellular portions of the Notch receptor. The cleaved 
proteins are transported to the membrane where they associate non-
covalently to form the functional Notch receptor. A Notch ligand expressed 
on a neighboring cell can then bind to the extracellular portion of the 
receptor. This leads to cleavage by an ADAM protease. This cleavage 
releases the extracellular portion, which remains bound to the ligand and 
is endocytosed into the ligand-bearing cell. The γ-secretase complex then 
cleaves the Notch receptor and releases the intracellular portion (NIC). NIC, 
which is the active form of Notch, translocates to the nucleus, where it 
causes the dissociation of a co-repressor complex from the CBF-1 
transcription factor, and recruits a co-activator complex, resulting in 
transcription of various target genes including the Hes and Hey family of 
genes. Abbreviations: ADAM = a disintegrin and metalloprotease. Figure 
courtesy of Brian Bonish, MD, PhD. 
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portion of Notch 4, which is functionally active. Thus, the cells constitutively expressed 
activated Notch-4 resulting in altered proliferation of immature ductal cells. Similarly, the 
Notch-1 gene was identified as a target of MMTV insertion (reviewed in (176)).  
 
  In human breast cancers, Notch expression is also elevated. In one study, seven 
primary breast ductal carcinomas were immunostained for Notch-1 and showed high 
levels of Notch-1 expression compared to normal breast cells (177). In these samples, 
four of the seven samples stained positive for the h-Ras oncogene. Those that stained 
positive for h-Ras showed strong but diffuse staining for Notch-1, whereas, h-RasV12 
negative cells showed only a few cells that had strong staining for Notch-1 (177).  
 
 Reedijck et al. used in situ hybridization studies to show that elevated Notch-1 
and Jag-1 were associated with poor prognosis in breast tumors from patients (178). 
Patients that had tumors with high Jag-1 expression had a 5-year survival rate of 42%  
versus 65% for patients with low Jag-1 expression with a median survival of 50 months 
for the former and 83 months for the latter. Some tumors (12/40, 30%) with high levels of 
Jag-1 belonged to the basal subtype of breast cancer while the majority did not (28/40, 
70%). Elevated Jag-1 was a predictor of poor outcome regardless of the type of breast 
cancer (178). This laboratory confirmed their work using an additional 887 breast cancer 
samples. They found elevated Jag-1 expression was associated with basal-type breast 
cancer and that disease free survival was significantly reduced when Jag-1 was 
overexpressed at both the mRNA and protein levels (179). 
 
 Cohen et al. further looked at the effect of Jag mediated Notch signaling in breast 
cancer (180). They identified that triple-negative breast cancer expressed higher levels 
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of Jag-1 compared to other types of breast cancer cell lines. Knockdown of Jag-1 using 
an siRNA approach resulted in a significant reduction in proliferation. Microarray profiling 
of triple-negative breast cancer cell lines (HCC1143, MDA-MB-231) transfected with 
siJag-1 was done and a comparison made against control transfected cells. The authors 
determined that cyclin D1 was highly downregulated in siJag-1 transfected MDA-MB-231 
cells. Additionally, when Notch-1 and/or Notch-3 were knocked-down, cyclin D1 
expression was also reduced. Notch-3 had a much greater effect on levels of cyclin D1 
than Notch-1 (180).  
 
 Stylianou et al. studied the expression of Notch receptors and ligands in various 
breast tumors and breast cancer cell lines and found further evidence for aberrant Notch 
signaling in breast cancer (181). They showed Notch-1, Notch-3, Dll-4, Jag-1 and Jag-2  
were expressed in normal breast epithelial cells. Expression of Notch-2, Notch-4, Dll-1 
and Dll-3 were not examined. Using immunohistochemistry, they showed that Notch was 
expressed in the luminal epithelium. Next, they stably transfected immortalized normal 
breast epithelial cells (MCF10A) with a plasmid containing activated Notch-1. They 
showed these transformed cells grew uncontrollably in culture, formed colonies well in 
soft agar, and apoptosis was not induced in transformed cells treated with the kinase 
inhibitor staurosporine, or DNA damaging agents melphalan and mitoxantrone while 
there were high levels of apoptosis in untransformed cells as well as growth inhibition 
and poor colony formation. In addition, a panel of breast tumors and cell lines of various 
breast cancer phenotypes was studied for the expression of activated Notch. All samples 
tested showed increases in activated Notch and downstream target Hey-1 by Western 
blotting. Finally, the authors showed that by overexpressing, Numb, a negative regulator 
of Notch, they could reverse the transformation of the cell lines tested (181). In a 
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separate study, Pece et al. showed that Numb protein expression as determined by 
immunohistochemistry was shown to be decreased in 50% of 321 breast cancer patient 
samples tested (182).  
 
  Rizzo et al. showed that Notch-1 or Notch-4 levels were elevated in various 
infiltrating breast tumor samples compared to normal breast tissue using 
immunohistochemistry (183). ERα-negative cell lines (MDA-MB-231, and T47D-C42) 
showed higher levels of Notch activation than ERα-positive cell lines (MCF7, T47D-A18) 
or the HER2 overexpressing cell line SKBR3. The data also showed that estrogen 
inhibits Notch signaling (183). The authors proposed that estrogen inhibits Notch 
signaling, in part, through ERα by inhibiting γ-secretase cleavage of Notch. Moreover, 
Notch-1 was shown to induce Notch-4 expression in MCF7 cells. Notch-4 expression 
was associated with Ki67 (a proliferation marker) in primary tumor samples. In other 
words, cells expressing Notch-4 were also proliferating; therefore, Notch-4 may be a 
therapeutic target for breast cancer. In MCF7 cells, inhibition of ERα (by anti-estrogens, 
estrogen deprivation, or loss of ER) led to higher levels of Notch-1 activity when 
compared to conditions where estrogen was present; this induced expression of Notch-4 
and lead to an increase in proliferation and invasion of these cells. The exact 
mechanism for invasion was not defined but in the absence of Notch-1 or Notch-4 led to 
decreased invasion of MDA-MB-231 cells and introduction of the activated form of 
Notch-1 (NIC 1) in MCF7 cells increased invasion through matrigel.  
 
 Osipo et al. demonstrated that overexpression of HER2 suppressed Notch-1 
activity and treatment with trastuzumab or a dual EGFR/HER2 tyrosine kinase inhibitor 
reversed this effect (184). Furthermore, they showed that cell lines, including BT474, 
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SKBR3 and MCF7/HER2-18 overexpressing HER2, had low levels of Notch activity as 
measured by a CBF-1 luciferase reporter assay compared to MDA-MB-231 cells and 
MCF7/Neo cells. In the presence of trastuzumab, Notch-1 activity was increased as 
were Notch targets Hey-1, Hes-1 and Deltex-1. In the presence of γ-secretase inhibitors 
and trastuzumab, Notch activity was decreased and apoptosis increased by 20%-30% in 
trastuzumab sensitive BT474 cells. These data suggest that Notch-1 might play a role in 
the resistance of breast cancer cells to trastuzumab, which can be reversed by inhibiting 
Notch-1 (184).  
 
 Finally, Notch-3 was shown to have a critical role in HER2-negative breast 
cancer cells. Yamaguchi et al showed that in breast cancer cell lines that were HER2-
negative (MCF7, HCC1419, and MDA-MB-468) expressed higher levels of Notch-1 and 
Notch-3 than HER2-positive cells. When Notch-3 was specifically inhibited using siRNA 
a significant decrease in cell proliferation in HER2-negative cells was observed, but this 
effect was only seen in one HER2-positive cell line (HCC1419). However, a knockdown 
of Notch-1 did not have this effect. Furthermore, apoptosis was induced in a HER2-
negative breast cancer cell line after transfection with siNotch-3. Similar results were 
observed when Jag-1, or Jag-2 were knocked-down. These data suggest that Notch-3 is 
important in the proliferation and survival of HER2-negative breast cancer cells and may 
be a therapeutic target to attempt to eliminate this type of cancer (185).   
 
Gamma-Secretase Inhibitors 
γ-secretase is a multi-subunit protease which consists of a catalytic subunit 
(presenilin-1, presenilin-2), Pen-2, Aph1 and Nicastrin (186). γ-secretase is required for 
the activation of all four Notch receptors, and γ-secretase inhibitors (GSIs) have been 
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shown as effective agents in blocking Notch signaling. At this point, it should be noted 
that γ-secretase not only cleaves Notch, but also has other intramembranous targets 
including CD44, E-cadherin and ERBB4 (186). Given the link between Notch and 
cancer, inhibition of Notch signaling has been proposed as a strategy for cancer 
treatment. Studies using GSIs have shown dramatic reductions in tumor burden in 
xenograft models (187, 188). Based on these promising results, GSIs have now moved 
into Phase I clinical trials in breast cancer.  
 
 Several studies have illustrated the effectiveness of using GSIs to treat cancers. 
Before going into details it is important to mention that these studies used at least one of 
the following GSIs: Z-Leu-Leu-Nle-CHO (LLNle, EMD Biosciences), LY411,575, or 
MRK003. LLNle is a tripeptide GSI, which has an aldehyde group that can inhibit serine 
proteases including calpain when used at high concentrations (187). This GSI has also 
been shown to inhibit the proteosome in breast cancers at concentrations higher than  
10 µM (L. Miele unpublished data). Therefore, this drug must be used at lower 
concentrations to inhibit Notch signaling without blocking proteosome activity. Other 
GSIs, which are peptidomimetic or small molecule γ-secretase inhibitors, LY411,575 or 
MRK003 respectively, used in our studies do not have aldehyde groups and have not 
been shown to inhibit calpain or other serine proteases (187).  
 
  Rizzo et al. used 1 µM LLNle, to inhibit Notch activation, and demonstrated 
growth inhibition in the cell lines tested including T47D-A18, MCF7, T47D-C42 and 
MDA-MB-231 cells (183). Curry et al. showed that treatment of Kaposi’s sarcoma cell 
lines and primary tumor cells with either of two different GSIs resulted in a G2/M growth 
arrest followed death via mitotic catastrophe and apoptosis (187, 189). Moreover, 
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treatment of established Kaposi’s sarcoma xenografts with LLNle led to growth inhibition 
and tumor regression (187). Chen et al. found that lung tumors treated with MRK003 had 
increased levels of apoptosis compared to the control (190). Finally, Konishi et al., using 
a lung cancer model showed that treatment with MRK003 decreased cell proliferation, 
inhibited Notch-3 signaling, and induced apoptosis (191). In another study, Qin et al. 
showed that LLNle had anti-neoplastic activities in melanoma (188). However, he later  
showed that LLNle, whose structure is similar to MG132 (a potent proteosomal inhibitor 
(reviewed in (192)), inhibited the proteosome under experimental conditions, which was 
responsible for the observed cell death (193).  
 
Notch and Breast Cancer Stem Cells 
 Several studies have linked the Notch pathway to breast CSCs. Farnie et al. 
showed that recurrence (at 5 years) of DCIS was increased in patients whose samples 
stained positive for NIC (194). They also found that mammosphere formation efficiency 
from DCIS samples was higher than in normal breast tissue. When treating 
mammospheres with an anti-Notch-4 antibody or a GSI (DAPT), the authors found a 
decrease in mammosphere formation efficiency, but did not see evidence of cell death 
under their experimental conditions (194).  
 
 Sansone et al. showed that mammospheres derived from MCF7 cells and 
primary ductal carcinoma samples expressed stem cell-associated genes such as Bmi-
2, CD44, Oct-4 and CD133 (195). They reported that Notch-3 was critical to 
maintenance of mammospheres as MCF7 cells transduced with siNotch-3 showed a 
decrease in mammosphere size, which is consistent with inhibition of progenitor 
proliferation (not self-renewal). Previously, these authors had found Notch-3 along with 
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p66Shc (a mammalian longevity modulator) and Jag-1 promote self-renewal (as 
mammospheres) under hypoxic conditions. These authors pursued Notch-3 because its 
overexpression has been shown to cause tumors in mice and because the Notch 
pathway can interact with hypoxia inducing factor (HIF) to promote a stem-like 
phenotype (196, 197). Furthermore, Notch-3 was highly expressed in mammospheres 
derived from tumors as compared to normal tissue (128, 195, 198). 
 
    Clearly, there is ample evidence that Notch signaling plays an important role in 
breast cancer and the stem-like population. Breast cancer cells express higher levels of 
activated Notch and the ligand Jag-1 than normal breast tumor cells, which is associated 
with a poor prognosis. Therefore, targeting this pathway may have clinical relevance.  
 
Cell Death 
 Cell death can occur in several different ways: necrosis, autophagy, mitotic 
catastrophe, and apoptosis. These will be briefly summarized below with the focus being 
on apoptosis. 
 
  Necrosis is an unregulated form of cell death characterized by swelling and 
rupturing of the cell membrane degeneration and release of organelles. It is often 
caused by trauma, infection, or inflammation. In vivo this results in the accumulation of 
cellular debris in the areas that can be detrimental to the health of the surrounding 
tissue. Necrosis also has an effect on ion transport and pH balance. The direct 
mechanism of action of necrosis is not clear (199).  
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 Autophagy is a form of cell death in which cellular organelles are degraded by 
lysosomes. The morphology of cells undergoing autophagy includes blebbing of the cell 
membrane and an increase in autophagic vesicles. These vesicles, which form in the 
endoplasmic reticulum, contain organelles and cellular material and fuse with 
lysosomes, resulting in their degradation. On the molecular level, PI3K and target of 
rapamycin (mTOR) may be involved in autophagy. mTOR negatively regulates 
autophagosome formation. The role of autophagy in cell death is still not fully understood 
but dysregulated autophagy has been implicated in several diseases including cancer 
(199).  
 
 Mitotic catastrophe refers to cell death following aberrant mitosis. It is initiated 
when a cell arrests during replication and is unable to repair the damage. Often, the cells 
arrest during interphase and form multiple micronuclei, which are characteristic of mitotic 
catastrophe. Ultimately, the cells will die via apoptosis, non-apoptotic cell death, or will 
enter senescence.  
   
 Apoptosis (programmed cell death) is characterized by cell shrinkage, membrane 
blebbing, chromatin compaction, and DNA fragmentation that eventually leads to the 
phagocytosis and elimination of the cell (200). It can be divided into three stages. First, 
apoptosis is initiated by either a ligand (extrinsic pathway) or cellular stress such as 
ultraviolet light (intrinsic pathway); these will be discussed below. Following initiation, 
caspases are activated. Caspases are cysteine proteases that exist in an inactive form 
(procaspases) (reviewed in (201)). There are three families of caspases in humans: 
initiator (caspase -8, -9, and -10), executioner (caspase -3, -6, -7), and inflammatory 
(caspase-1,-4,-5, -11, and -12) caspases. The initiator caspases form a complex with 
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either death receptors or adaptor proteins and become activated by autoproteolytic 
cleavage, then are released as activated caspases. Caspase -8 and -10 will form a 
complex with the receptor and adaptor proteins called the death inducing signaling 
complex (DISC). Caspase-9 will form a complex with cytochrome c and an adaptor 
protein called Apaf-1 (apoptotic protease activating factor 1). Once activated, a “caspase 
cascade” occurs whereby the initiator caspases activate the executioner caspases. The 
executioner caspases then cleave downstream targets associated with cell structure and 
function, leading to cell death. Caspase-2 cleaves a pro-apoptotic protein Bid that 
promotes the release of cytochrome c from the mitochondria (202). Inflammatory 
caspases are mainly associated with cleaving interleukins, which are important in the 
inflammatory response, or activating caspases associated with the inflammatory 
response.  
 
The Extrinsic Pathway of Apoptosis 
  The extrinsic or death receptor pathway involves several members of the tumor 
necrosis factor (TNF) receptor superfamily. Fas, TNF-R1, TRAIL-R1 and TRAIL-R2 are 
cell surface receptors containing a conserved death domain in the cytoplasmic tail. 
Alternative designations for these receptors and ligands are listed in Table 2. When 
engaged by the appropriate ligand, the receptor trimerizes and recruits death domain-
containing adaptor proteins that interact with the death domain in the receptor’s 
cytoplasmic tail. These complexes of adaptor proteins are referred to as DISC.  
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 Each receptor recruits slightly different adaptor proteins to the DISC. Fas, TRAIL-
R1 and TRAIL-R2 interact with FADD while TNF-R1 interacts with TRADD. Once the 
DISC has formed, the death effector domain of FADD, for example, binds to procaspase 
8 (reviewed in (203)). The high concentration of procaspase-8 in the DISC leads to 
autoproteolytic cleavage releasing active caspase 8. This will then cleave executioner 
caspases-3, -6, or -7 resulting in cleavage of downstream apoptosis-associated targets 
such as DNA repair enzymes, cytoskeletal proteins, and nuclear proteins leading to cell 
death (reviewed in (204)). The extrinsic apoptotic pathways are summarized in figure 6.  
 
Other members of the TNF receptor superfamily contain TRAF interacting motifs 
in their cytoplasmic tails including TNF-R2, CD40, CD30, and RANK. Activation of these 
Full name Abbreviation Alternate abbreviation 
Tumor necrosis factor 
receptor-1, -2 
TNF-R1*,  
TNF-R2 
TNFRSF1A*, 
TNFRSF1B, CD120a*, 
CD120b 
Tumor necrosis factor 
receptor superfamily 6 
TNFRSF6  Fas, CD95, APO-1 
TNF-related apoptosis 
inducing ligand receptor -1, -2  
TRAIL-R1*,  
TRAIL-R2 
DR4*, DR5, CD261*, 
CD262 
Tumor necrosis factor alpha TNFα TNFSF2  
TNF-related apoptosis 
inducing ligand  
TRAIL TNFSF10, APO2L, 
CD253 
Tumor necrosis factor (ligand) 
superfamily member 6 
TNFRSF6L FasL, CD95L 
Table 2: Alternative names for extrinsic apoptotic pathway ligands and 
receptors. Where two receptors are present the asterisk (*) identifies the 
corresponding pairs of abbreviations. DR = death receptor, TNFRSF = 
tumor necrosis factor receptor superfamily APO = apoptosis antigen 
ligand 
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receptors recruits TRAF family members resulting in activation of signal transduction 
pathways including JNK, p38, and NF-κB. These receptors may play a role in apoptosis, 
but are also involved in cellular proliferation and differentiation.  
 
The Intrinsic Pathway of Apoptosis 
 The intrinsic or mitochondrial pathway of apoptosis is initiated by a genotoxic 
stress such as ultraviolet light or cytokine deprivation. This form of apoptosis involves 
the Bcl-2 family, which consists of both pro- and anti-apoptotic members. There are over 
20 Bcl-2-related proteins with most of the anti-apoptotic proteins found in the 
mitochondria, endoplasmic reticulum or nuclear envelope while the pro-apoptotic 
members are often found in the cytosol. 
 
 In healthy cells, Bax and Bak, two pro-apoptotic Bcl-2 family members, remain as 
monomers in the cytosol or loosely associated with membranes (reviewed in (205)). 
When a death signal is received, they undergo a conformational change and translocate 
to the mitochondria. Then Bax and Bak oligomerize and form pores in the mitochondrial 
membrane through which cytochrome c is released. Once cytochrome c is released from 
the mitochondria, it binds to Apaf-1 and procaspase-9 via its caspase recruitment 
domain. Together, these proteins form the apoptosome and activate the executioner 
caspases -3, -6, or -7 (199, 206).  
 
  Bcl-XL, an anti-apoptotic Bcl-2 related protein, inhibits cell death by binding to 
Apaf-1 and preventing formation of the apoptosome (reviewed in (204)). In contrast, Bcl-
2 prevents apoptosis by blocking activation of Bax or Bak (205). Other pro-apoptotic  
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proteins include Smac/Diablo (second mitochondrial derived activator caspase protein) 
and Omni/HtrA2, which antagonize the inhibitors of apoptosis (IAPs) that bind to and 
inhibit activated caspases. The IAP family including XIAP (BIRC4), c-IAP1 (BIRC2), and 
c-IAP2 (BIRC3), inhibit apoptosis by binding caspases and preventing their activity 
(reviewed in (206)). XIAP binds to the active site of caspase-3 and -7, and also inhibits 
caspase-9 by preventing its dimerization. c-IAP2 is an E3 ligase that ubiquitinates 
caspase-3 and -7, whereas, c-IAP1 has been implicated in the degradation of TRAF2 
which is an adaptor protein that binds to TNF-R1 and is responsible for activation of the 
JNK pathway (206, 207). Taken together, the balance between pro- and anti-apoptotic 
proteins plays a key role in determining whether a cell undergoes apoptosis.  
 
 Although the intrinsic and extrinsic apoptotic pathways are distinct, there is 
crosstalk between the pathways, and they converge at activation of the effector 
caspases. Activation of caspase-8 by the extrinsic pathway can lead to the cleavage of 
Bid to t-Bid (truncated Bid). t-Bid localizes to the mitochondria and induces cytochrome c 
release by promoting the formation of Bax and Bak oligomers (208). Bid is also cleaved 
by caspase-2 (202). This caspase can be activated via TNF-R1 resulting in induction of 
the caspase cascade and apoptosis (reviewed in (209, 210)).  
 
Breast Cancer Chemotherapy and Apoptosis 
 Breast cancer chemotherapy results in the apoptosis of tumor cells. Both 
malignant and benign breast tumor cells have been shown to express members of the 
extrinsic and intrinsic apoptotic pathway including TRAIL receptors and members of the 
Bcl2 family (211). Single nucleotide substitutions, which resulted in missense mutations 
in the death domain or regions flanking the death domain of TRAIL-R1 or TRAIL-R2, 
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have been identified in metastatic breast cancer (212). The authors tested the effects of 
these mutations in TRAIL-R1, and TRAIL-R2 by creating constructs with the mutations 
and transfecting them into HEK293 cells then testing for apoptosis. They observed a 
significant decrease in apoptosis in these cells (212). With respect to the intrinsic 
apoptotic pathway, MCF7 cells increase Bcl-2 expression in response to estrogen. When 
these ERa-positive cells are treated with an anti-estrogen, such as Fulvestrant, Bcl-2 
expression is decreased. This decrease of Bcl-2 in this system results in greater 
sensitivity to the chemotherapeutic agent Adriamycin (213). Most chemotherapeutic 
agents utilize the intrinsic pathway to induce cell death (reviewed in (204)).  
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Figure 6: A Summary of the Extrinsic and Intrinsic Apoptotic Pathways. Upon 
ligand binding to one of the receptors (TNF-R1, Fas, or TRAIL-R1,-R2, a 
downstream recruitment of various adaptor proteins occurs. In the case of TNF-
R1 TRADD, SODD, FADD, RIPK2, RAIDD are recruited. FADD will bind to 
procaspase 8/10 through its death effector domain, which will then be activated 
by autoproteolytic cleavage. Caspase 8 will then activate either caspase -3, -6, or 
-7 (the executioner caspases) or cleave a Bcl-2 proapoptotic protein Bid that will 
then translocates to the mitochondria and activate Bax and Bak. Caspase-2, 
which binds to RAIDD via its CARD domain, can also cleave Bid resulting in t-Bid. 
These will allow for the release of cytochrome c from the mitochondria, which will 
bind to Apaf-1, and recruit caspase-9 via its CARD domain. Caspase 9 will bind 
activate executioner caspases 3, 6, 7. Bcl2 is an anti-apoptosis protein that 
prevents the release of cytochrome c by interfering with the production of Bax and 
Bak channels. In addition, Bcl2 can be regulated by the JNK pathway, which can 
be activated through TNF-R1, and a MAPKKK protein ASK. ASK can also 
phosphorylate MKK7 which can then activate JNK. JNK has also been implicated 
in inhibition of Bcl2. XIAP is an inhibitor of apoptosis, which binds to and 
inactivates caspase-3. Smac/Diablo are pro-apoptotic proteins found in the 
mitochondria, which will inhibit XIAP and inhibitors of apoptosis. Abbreviations 
XIAP= X-inhibitor of apoptosis; TNF-R1 = Tumor necrosis factor receptor 1; 
CARD = Caspase recruitment domain; FADD= Fas associated with death 
domain; SODD = Silencer of Death Domains; TRADD= TNFRSF1A-associated 
via death domain; RAIDD = RIP-associated ICH1/CED3 homologous protein with 
death domain; RIPK2 = receptor interacting serine-threonine kinase 2; MKK7 = 
mitogen activated protein kinase kinase 7; ASK = apoptosis signal regulating 
kinase; Apaf-1 = Apoptotic peptidase activating factor-1; JNK = c-Jun N-terminal 
kinase; TRAIL = TNF related apoptosis inducing ligand    
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Apoptosis in the Putative Cancer Stem Cells 
 Studies have recently begun to approach the question of which apoptotic 
pathways may be used by CSCs. For example, TRAIL-R1 has been shown to be 
upregulated in the SP compared to the non-SP in colon cancer cells (214). The SP cells 
were also much more sensitive to TRAIL killing than their counterparts (214). The 
CD133-positive subset of MCF7 cells was found to overexpress FLIP (FLICE like 
inhibitory protein), an anti-apoptotic protein that inhibits caspase-8 by binding to it and 
preventing DISC formation (215). This study also showed that XIAP was upregulated in 
the CD133-positive fraction of glioblastoma cells (216).  
 
 The intrinsic pathway has also been implicated in CSC apoptosis. In leukemia, 
elevated Bcl-2 levels were found to protect hematopoietic stem cells from 
chemotherapeutic agents (217). In glioma stem cells, the anti-apoptotic protein Mcl-1 
was highly expressed leading to resistance to treatment with a Bcl-2 inhibitor (218). 
Finally, Bcl-2 and Bcl-XL were overexpressed in the CD133-positive subset of 
glioblastoma cells compared to the CD133-negative population.   
   
While most chemotherapeutic agents engage the intrinsic apoptotic pathway, 
they are not always effective which may be due to the presence of the stem-like 
population. This may be due to the high levels of ABC transporters found in stem-like 
and early progenitor cells that efflux various toxic insults including chemotherapeutic 
agents from the cells. Drugs triggering signaling through the death receptor pathway can 
be used in combination with chemotherapy in order to promote cell death in tumors and 
possibly CSCs. Ligands of the extrinsic pathway do not need to enter the cell in order to  
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initiate a response. Therefore, members of the extrinsic pathway are an excellent target 
in CSCs for treatment of cancers since they can kill cancer cells from the outside of the 
cell and avoid efflux by the ABC transporters. 
 
Apoptosis via the c-Jun N-terminal Kinase Pathway 
 Members of the JNK pathway are part of the MAPK family of kinases. Cellular 
stresses, cytokines and chemotherapeutic drugs can activate the JNK pathway which 
consists of three JNK proteins (JNK-1, -2, and -3). In order to activate JNK, a MAP3K 
(mitogen activated kinase, kinase, kinase) such as ASK-1, (apoptosis signal-regulating 
kinase 1) MEKK-1, -4 (MAPK/ERK kinase kinase-1, -4), or MLK-3 (mixed lineage kinase) 
needs to phosphorylate a downstream MAP2K (mitogen activated kinase kinase) such 
as MKK4 or MKK7. One of these kinases then phosphorylates JNK on a threonine-
proline-tyrosine motif in the active site (219). In order to enhance JNK activation, MKK7 
and JNK can bind to JIP1 (JNK interacting protein 1), a scaffold protein which allows the 
kinases to phosphorylate each other in close proximity (220).  
  
 In a study done by Harkin et al., the breast cancer cell lines MDA-MB-435 and 
HCC1937 were engineered to stably express BRCA-1 then screened to identify genes 
that were upregulated after induction of BRCA-1. The authors showed elevated levels of 
GADD45 (a DNA damage response gene), which then activated the JNK pathway by 
binding to the MEKK-4 (MKK4) (221) and led to apoptosis in a p53-independent manner 
(222). In the breast cancer cell line MBR62, BRCA-1 led to the upregulation of GADD45 
and the JNK/SAPK pathway, which led to apoptosis (222).  
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Thangaraju et al. showed the JNK pathway was activated in MCF7 cells following 
serum deprivation. Interestingly, Fas/FasL upregulation were observed in response to 
JNK activation, which indicates that JNK may be upstream of the Fas pathway (223). 
Similar results were shown in ovarian carcinoma cells treated with cisplatin, which led to 
phosphorylation of c-Jun, and transcription of Fas ligand. When the JNK pathway was 
blocked, lower levels of Fas ligand mRNA and apoptosis were observed (224). Koyuturk 
et al. treated cells with simvastatin (commonly used to treated high cholesterol but also 
implicated in reduction of cancer) to show MCF7 cells and MDA-MB-231 engaged JNK 
to induce apoptosis (225).  
 
Activated Notch as an Inhibitor of the c-Jun N-terminal Kinase Pathway.  
 Previous studies have linked the JNK and Notch pathways. Kim et al. showed 
that presenilin-1 (a component of the γ-secretase complex) prevented the activation of 
the JNK pathway in HEK 293 cells after exposure to ultraviolet light (226). They 
speculated that this inhibition might be due to activated Notch. Later, they showed that 
the activated form of Notch-1 interacted with JIP-1 thereby preventing the activation of 
JNK (227).  
 
p38 Mitogen Activated Protien Kinase  and Apoptosis      
 The p38 MAPK pathway has also been implicated in apoptosis. The p38 pathway 
can be activated by stress or cytokines such TNF-α, heat shock and some 
chemotherapeutic agents (Paclitaxel, Vincristine and Vinblastine). This pathway involves 
the activation of a MAP3K such as ASK1, or p21 activated kinase, which then  
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phosphorylates a MAPK2K, MKK-3 or MKK-6 at threonine and tyrosine residues leading 
to the activation of p38 MAPK (228). Downstream targets of p38 include ATF-2, MEF-2 
and CDC25 to name a few. GADD45 was also shown to be an upstream mediator of p38 
in human keratinocytes (229). In GADD45 null mice, p38 expression was low compared 
to mice with normal levels of GADD45 (229). The p38 MAPK pathway has also been 
implicated in the apoptosis of ovarian carcinoma cells. Seidman et al. showed that high 
concentrations of Taxol (1 µM-10 µM) increased p38 levels within two hours, and they 
continued to be active for up to 24 hours in ovarian carcinoma cells (230). Inhibition of 
p38 with SB203580 partially protected ovarian carcinoma cells from Taxol induced 
apoptosis. The p38 MAPK pathway was also induced (as determined by Western 
blotting) in endothelial cells treated with TNFα. In addition, capase-8 activation and 
levels of tBid were decreased in the presence of p38-MAPK inhibitor. These data link the 
p38 MAPK pathway with TNF signaling in endothelial cells. 
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CHAPTER 2 
 MATERIALS AND METHODS 
 
Breast Cancer Cell Lines: The ERα-positive, estrogen-responsive breast cancer cell 
lines, T47D-A18 and MCF7, were grown under estrogen-containing conditions (RPMI-
1640, 10% fetal bovine serum (FBS), 1% nonessential amino acids, 2 mmol/l L-
glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 6 µg/ml insulin). T47D-C42 
cells, an ERα-negative, hormone-nonresponsive breast cancer cell line, was grown 
under estrogen-deprived conditions (phenol-red free RPMI-1640 media, 10% charcoal-
dextran stripped FBS, 1% nonessential amino acids, 2 mmol/l L-glutamine, 100 U/ml 
penicillin, 100 µg/ml streptomycin, and 6 ng/ml insulin). The T47D-A18 and T47D-C42 
cell lines were originally subcloned from the T47D line and characterized in the 
laboratory of Dr. V. Craig Jordan. They have been extensively used as a model of 
acquired resistance to endocrine therapy (231, 232). Both cell lines were the kind gift of 
Dr. Debra Tonetti (University of Illinois at Chicago, Chicago, IL). MDA-MB-231 breast 
cancer cells, an ERα-negative, PR-negative, HER2-negative (triple-negative), and 
claudin low cell line, was grown in IMEM media containing 5% FBS, 1% nonessential 
amino acids, 2 mmol/l L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. 
BT474 and SKBR3 breast cancer cells, which are ERα-positive and negative 
respectively and both overexpress Her2/neu, were grown in IMEM media containing 
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10% FBS, 1% nonessential amino acids, 2 mmol/l L-glutamine, 100 U/ml penicillin, 100 
µg/ml streptomycin. MDA-MB-468 cells, an ERα-negative, PR-negative, HER2-negative 
(triple-negative) cell line was grown in DMEM-Ham’s F12 (50:50), 10% FBS, 2 mmol/l L-
glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. Table 2 summarizes some 
key characteristics of the cell lines used in these studies. LTK-Jag-1 cells, a mouse L 
cell line overexpressing Jag-1, was grown in DMEM containing 10% FBS, 2 mmol/l L-
glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. Some characteristics of 
these cell lines are summarized in Table 3.  
 
Primary Breast Cancer Cells From Pleural Effusions: Pleural effusions were collected 
from patients undergoing thoracentesis for metastatic breast cancer with informed 
consent (LUMC). Effusions were diluted 1:1 in sterile phosphate-buffered saline (PBS) 
(Hyclone), the cells pelleted by centrifugation, and resuspended in sterile PBS. For all 
protocols, PBS will refer to PBS without calcium and magnesium unless otherwise 
specified. The cells (25 ml) were layered on 15 ml Ficoll-Paque (GE Healthcare, 
Piscataway, New Jersey) density gradient. Cells were then collected from the interface 
following a 30-minute centrifugation at 500 x g at room temperature. The cells were 
washed three times with PBS, counted, and used in various experiments. Table 4 lists 
the pleural effusion samples that were obtained.  
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Notch Inhibitors: Where indicated, cells were treated with one of three structurally 
distinct GSIs: Z-Leu-Leu-Nle-CHO (LLNle; EMD Biosciences, San Diego, CA), LY-
411,575 (N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo- 
6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide) (Dr. Todd Golde, Mayo Clinic, 
Jacksonville, FL) or MRK003 (Merck pharmaceuticals, Whitehouse station, New Jersey). 
LLNle is a tri-peptide GSI, LY411,575 is benzodiazepine peptidomimetic GSI, and 
Table 3: A summary of breast cancer cell lines utilized in our studies. ERα 
= estrogen receptor alpha, PR = progesterone receptor. WT= wildtype, M= 
mutant. Brackets [ ] indicate that information was obtained from only the 
mRNA and not protein. Information obtained from Neve et al. (233).  
 
Table 4: A list of the primary samples obtained from the Cardinal 
Bernardin Cancer Center, LUMC. BC-PE = breast cancer pleural 
effusion sample, BC-AS = Breast cancer ascites sample. The asterisk 
(*) indicates that these two samples were obtained from the same 
patient. ** The ER/PR/Her2 status represents the phenotype of the 
original tumor. 
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MRK003 is a cyclic sulfonamide small molecule GSI (234). MRK003 is an experimental 
drug synthesized by the Merck company. It is the research equivalent of the clinical drug 
MRK0756 that is currently in clinical trials. MRK0756 is not appropriate for animal 
studies; therefore, the MRK003 compound is utilized in preclinical studies. The half-life 
of the LY411,575 has been reported as 2 hours in vivo (235). To maintain inhibition of 
Notch signaling in vitro, we routinely replenish this drug every 6 hours (187, 189). LLNle 
is more stable and is generally replenished every 48 hours; while MRK003 is stable for 
96 hours in vitro. We replenished MRK003 every 4-5 days based on the experimental 
protocol. All three agents were suspended in dimethyl sulfoxide (DMSO). A specific 
Notch decoy protein, recombinant human Notch-1 Fc chimera, and a control protein, 
recombinant human IgG1 Fc protein, were purchased from R&D Systems (Minneapolis, 
MN). Both reagents were resuspended in mammosphere media. A web-based calculator 
(molbio.ru/eng/scripts/01-04.html) was used to determine the concentration of each 
protein in micromoles/ml from the molecular weight.  
 
Kinase inhibitors: A variety of kinase inhibitors were utilized including: JNK inhibitor II (10 
mM), PD 98059 (MEK I inhibitor) (75 mM), SB203580 (p38 Inhibitor) (30 mM), NF-κB 
activation inhibitor (1 mM), or AG490 (10 mM). Each inhibitor was resuspended in 
DMSO at the listed concentrations and stored at -20 °C. The inhibitors were used at 1X, 
2X and 10X their published IC50 concentrations. These inhibitors were purchased from 
EMD Biosciences.  
 
Side Population Analysis: T47D-A18 and T47D-C42 cells were loaded with Vybrant 
DyeCycle Violet (DCV, Invitrogen, Carlsbad, CA), an alternative to Hoechst 33342, as 
described (135). Briefly, cells were suspended at 1 x 106 cells/ml in DMEM containing 
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10% FBS and 10 mM HEPES (N-2-Hydroxyethylpiperazine-N'-2-Ethanesulfonic Acid) 
then incubated for 90 minutes at 37 oC with 5 µl (25 µM) of DCV. To confirm the SP had 
been identified, one sample of cells was pretreated for 30 minutes with 50 µM – 100 µM 
verapamil hydrochloride, an inhibitor of ABC transporters, to block DCV efflux. Variability 
problems in terms of reducing the SP were occasionally encountered with verapamil 
treatment, which has been previously reported (236). The cells were placed on ice, 
propidium iodide (PI) (2.5 µg/ml) added, and the cells immediately analyzed on a FACS 
Aria flow cytometer (BD Biosciences) by the Loyola University FACS Core Facility. After 
exclusion of dead cells with PI (excitation wavelength 536 nm emission wavelength 617 
nm), the SP was identified by exciting DCV using the 405 nm wavelength. DCV emits at 
two different wavelengths 450 nm and 670 nm. The dye when added at saturating 
conditions will bind to DNA and emit at 450 nm while dye that has not bound to DNA 
emits at 670 nm. Since the unbound dye can be effluxed from the cell a decrease in 
fluorescence is observed at the 670 nm wavelength. Therefore, the SP can be identified 
as the small subset of cells with relatively low fluorescence compared to the bulk cell 
population (non-SP cells).  
 
Mammosphere Formation: Primary mammospheres were generated from single cells by 
seeding ultra-low attachment plates (Corning, Lowell, MA) with approximately 20,000 
cells/ml in mammosphere media [mammary epithelial basal media (Lonza, Walkersville, 
MD), 2% B27 (Invitrogen), 20 ng/ml EGF (BD Biosciences), 20 ng/ml bFGF (BD 
Biosciences), 4 µg/ml heparin (Sigma-Aldrich, St. Louis, MO)] as described (237). A total 
of 60,000 cells (in a 3 ml volume) were added to each well in a 6-well ultralow 
attachment plate or 360,000 cells (in a 10 ml volume) to a 10 cm ultralow attachment 
plate.  
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To passage mammospheres, cells were collected by centrifugation, 200 x g for 5 
minutes, incubated for 3-5 minutes in 0.125% trypsin, and then cell clusters disrupted by 
pipetting through a 200 µl pipet tip. Microscopic examination was used to ensure single 
cell suspensions (≥99%) were obtained, and cell viability determined using trypan blue 
exclusion (1:2) prior to plating at 1000 cells/cm2 in mammosphere media on ultra-low 
attachment plates (237). These cells were allowed to form secondary mammospheres 
and these were used for analysis.  
 
 In experiments determining the effect of GSI on mammosphere formation, primary 
mammospheres were prepared then treated after 24 hours with GSI or DMSO as a 
control. Twenty-hours later (48 hours after the start of the experiment) the 
mammospheres were dissociated as stated above and secondary mammosphere 
cultures established in the presence of fresh GSI or DMSO. Forty-eight hours after 
establishment of secondary cultures, mammosphere formation was quantitated by 
counting the number of mammospheres in 10 random, high-powered fields (HPF) per 
experimental condition. Any group of cells containing more than 4 cells was considered 
a mammosphere. Where indicated, cells were retreated with GSI or DMSO at 96 hours 
after establishment of secondary cultures. In studies utilizing the specific Notch decoy 
protein, primary mammospheres were dissociated and secondary mammosphere 
cultures initiated in a 96-well ultralow attachment plate in the presence of recombinant 
human Notch-1 Fc chimera (3 µM) or recombinant human IgG1 Fc (3 µM) as a control. 
Mammosphere formation was evaluated 24 hours later.  
 
Immunostaining: Mammospheres were collected, centrifuged at 200 x g for 5 minutes 
and suspended in 100 µl of PBS. Cytospin cell preparations were then prepared using a 
  69  
   
Shandon Cytospin 2 centrifuge at 500 revolutions per minute for 5 minutes. Cytospins 
were fixed in 50:50 methanol:acetone for 10 minutes and immunostained using a highly 
sensitive avidin-biotin immunoperoxidase technique (Vectastain ABC kit, Vector 
Laboratories, Burlingame, CA) as described (238). After fixing, the cells were blocked in 
horse serum (1:200 dilution in PBS + 0.1% BSA) for 15-30 minutes. The primary 
antibodies used for these studies were purchased from Leica Microsystems 
(Bannockburn, IL) and were diluted in PBS + 0.1% BSA. These include cytokeratin 5 
(1:100) for progenitor cells, epithelial specific antigen (ESA) (1:500), cytokeratin 18 
(1:400) for luminal epithelial cells, CD10 (1:80) and cytokeratin 14 (1:20) for 
myoepithelial cells (237). Cells were incubated with the primary antibody for 1 hour at 
room temperature in a humidified chamber, and then the slides were washed in 0.01% 
FA Buffer (BD Biosciences) for 5 minutes. Next, the cells were incubated with a species-
specific secondary antibody (1:200) for 30 minutes at room temperature in a humidified 
chamber. Again, slides were washed in FA Buffer for 5 minutes. The avidin: biotinylated 
enzyme complex “ABC” reagent was added (1:100 for each reagent), incubated in a 
humidified chamber for an additional 30 minutes at room temperature, and washed with 
FA buffer for 5 minutes. A substrate, 3,3’-diaminobenzidine (DAB) (Vector laboratories), 
was prepared following the manufacturer’s instructions and added for color 
development. After an 8 minute incubation with DAB, the slides were washed with FA 
Buffer and counterstained with hematoxylin for 1 minute and washed with water 2 times 
once for 1 minute then for 5 minutes. Slides were mounted with Aquamount (Lerner 
Laboratories, Pittsburg, PA) and coverglass (Fisher Scientific Hanover Park IL).  
 
Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling (TUNEL) Assay: 
TUNEL staining was performed using the ApopTag peroxidase in situ apoptosis 
  70  
   
detection kit (Millipore) following the manufacturer’s instructions. Mammospheres 
derived from T47D-A18 cells were treated with 20 µM of MRK003 or DMSO for 24 or 48 
hours and used for cytospin cell preparations. The cells were fixed in 4% neutral 
buffered formalin for 10 minutes at room temperature, and post-fixed in cold 
ethanol:acetic acid (2:1) for 5 minutes at -20oC to permeabilize the cells. The slides were 
washed twice in PBS (5 minutes each), and then 50 µl microliters of equilibration buffer 
added to the slides for 5 minutes at room temperature. The buffer was removed and TdT 
enzyme was added followed by a 1-hour incubation at 37oC in a humidified chamber. 
The slides were then soaked in stop buffer agitated for 15 seconds followed by a 10-
minute incubation. Three 1-minute washes in PBS followed. The anti-digoxigenin 
conjugate was applied, incubated with the cells for 30 minutes in a humidified chamber, 
followed by four washes with PBS (2 minutes each). DAB was used as the substrate, but 
in this experiment, the nickel reagent was added to give a black color that is more easily 
discernable. The slides were incubated with DAB for 5 minutes, washed 3 times in water 
(1 minute each), and cells counterstained with methyl green (Vector Laboratories). 
Methyl green was added directly to the slides for 5 minutes at 60 oC and rapidly washed 
with water 2 times. The cells were then dehydrated in preparation for permanent 
mounting with Cytoseal 60 (Richard Allen Scientific Kalamazoo, MI). A permanent mount 
was required as methyl green is water soluble and is therefore not compatible with an 
aqueous mounting media.  
 
CD44,CD24, ESA Staining: Standard flow cytometry techniques were utilized for the 
identification of CD44+ and CD24low/- cells. Briefly, cultured cells were trypsinized to form 
a single cell suspension and washed twice with FACS buffer (1% FA buffer (Difco), 0.1% 
sodium azide, 1% FBS). Next, 5 x 105 cells were incubated with primary antibodies. 
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Following a 1-hour incubation on ice, the cells were washed twice with FACS buffer and 
centrifuged at 5 minutes at 200 x g to collect the cells. When unconjugated primary 
antibodies were used, the cells were then incubated for an additional hour on ice with 
conjugated, species-specific secondary antibodies directed against immunoglobulin. 
Following two washes with FACS buffer, the cells were fixed in 2% paraformaldehyde, 
pH 7.4. Each experiment included appropriate controls including unstained cells for 
setting the appropriate gates, and cells stained with each antibody individually 
(compensation controls). Compensation controls are required when analyzing samples 
stained with multiple antibodies to determine and remove the spectral overlaps between 
the fluors (239).  
 
For dual staining experiments, samples were incubated with CD24 (ML5, mouse 
IgG2a, BD Pharmingen) antibody at 5 µg/ml and CD44 (A020, EMD Biosciences) 
antibody at a 1:1000 dilution. Secondary antibodies included an allophycocyanin (APC) -
conjugated goat anti-rat Ig polyclonal antibody (BD Biosciences) used at a 1:20 dilution 
and an allophycocyanin-Cyanine 7 (APC-Cy 7) goat anti-mouse IgG2a antibody 
(Southern Biotech, Birmingham, Alabama) used at a 1:150 dilution (144). For triple 
staining experiments, a CD44-FITC (Clone 156-3C11) conjugated antibody (Cell 
Signaling Technologies, Beverly, MA) and an ESA (Clone HEA-125) –APC conjugated 
antibody (Miltenyi Biotech, Auburn, CA) (144) were both used at a 1:10 dilution. The 
CD24 antibody (FL-80) (Santa Cruz Biotechnology, Santa Cruz, CA) was used at a 1:50 
dilution and was detected with a PE-conjugated goat anti-rabbit IgG secondary antibody 
(1:200, Invitrogen). Based on published studies, the triple staining experiments included 
a few modifications from the standard protocol such as a PBS buffer containing 0.1% 
BSA + 2 mM HEPES was used instead of FACS buffer for resuspension of the cells. 
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Because these studies used a mixture of conjugated and unconjugated antibodies, the 
CD44-FITC antibody was added during the 1-hour incubation with the secondary 
antibody detecting CD24. During the last 10 minutes of this incubation, Fc blocking 
buffer (1:10, Miltenyi Biotech) was added followed by the ESA antibody. Although most 
staining procedures use longer incubation times, the manufacturer recommends only a 
10 minute incubation with the ESA-APC antibody. 
 
Aldehyde Dehydrogenase Activity (Aldefluor) Assay: The Aldefluor assay (Stem Cell 
Technologies, Vancouver, British Columbia, Canada) was performed according to 
manufacturer’s instructions. Cells were washed with PBS and suspended at 1x106 
cells/ml in assay buffer, and 5 µl of Aldefluor reagent was added to 1 ml of cells. 
Immediately, 500 µl of cells was transferred to a tube containing 5 µl of 
diethylaminobenzaldehyde (an ALDH inhibitor). Cells were placed in a 37o C water bath 
for 45 minutes then analyzed by flow cytometry using the FITC (488 nm wavelength) 
channel. By comparing the flow profiles of cells with and without the ALDH inhibitor, the 
ALDH-containing population can be readily identified. 
 
Quantitative Reverse Transcriptase Polymerase Chain Reaction (RT-qPCR): Total 
cellular RNA was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA) as directed 
by the manufacturer. Complementary DNA was synthesized by reverse transcription 
using 5.5 mM MgCl2, 500 µM dNTP (deoxynucleotide triphosphate), 2.5 µM oligo dT and 
2.5 µM random hexamers as a primer, 0.4 U/µL RNase inhibitor and 1.25 U/µL reverse 
transcriptase enzyme (Taqman Reverse Transcription kit, Applied Biosystems Foster 
City, CA). The reverse transcription reaction used 200 ng of RNA for each reaction. 
cDNA was synthesized by placing the reaction at 25oC for 10 minutes, 48 oC for 30 
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minutes, and 95 oC for 5 minutes. RT-qPCR was performed using an Applied Biosystems 
7300 sequence detection system (Foster City, CA) with Quantitect SYBR Green PCR 
reagents and Quantitect Validated Primer Sets (Qiagen) following the manufacturer's 
instructions. The validated primer sets were designed to span exon-exon borders 
preventing amplification of genomic DNA, and to prevent amplification of non-specific 
PCR products and primer-dimers. To help prevent PCR contamination, all reactions  
contained dUTP and 0.025 U/µL uracil DNA-glycosylase to destroy previous amplified 
product (240). Negative control samples containing yeast RNA (250 ng/ml, Applied 
Biosystems, Foster City, CA) instead of cDNA was used to monitor PCR contamination 
in every experiment. The RT-qPCR program was set as follows: 50 oC for 2 minutes, 95 
oC for 10 minutes, then 40 cycles of 95 oC for 15 seconds, 55 oC for 30 seconds, and 72 
oC for 30 seconds. Additionally, a dissociation curve was run for each experiment. In all 
experiments, only one peak was observed in the dissociate curve indicating that non-
specific amplification had not occurred. Amplification efficiencies for the primer sets were 
shown to be approximately equal using a validation experiment (Applied Biosystems, 
User Bulletin 2: Relative Quantitation of Gene Expression). Relative mRNA expression 
was calculated using the comparative method (described below) where expression of 
the target genes in each sample was normalized to β2-microglobulin expression (Applied 
Biosystems, User Bulletin 2: Relative Quantitation of Gene Expression).  
 
The comparative method is used to compare mRNA expression levels between 
two samples enabling a fold-change to be calculated. The Applied Biosystems 7300 
sequence detection system captures the fluorescent signal in each sample generated by 
binding of SYBR green to the double-stranded PCR product at the end of each PCR 
cycle. As the amount of SYBR green fluorescence is directly proportional to the amount 
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of PCR amplification, a plot of the data obtained at each cycle provides the necessary 
information to calculate relative mRNA expression. By setting a threshold value within 
the linear range of the amplification plot, but above the region where the non-amplified 
region is found, a CT (cycle threshold) value can be calculated. This value is defined as 
the number of cycles required for the fluorescent signal to cross the threshold. CT values 
are inversely proportional to the amount of target cDNA in the sample. The CT values are 
normalized against the CT values for β2-microglobulin to compensate for differences in 
the sample RNA (such as amount added or quality of the RNA that could affect 
amplification etc). This value is termed ∆CT. The ∆CT value for the control sample is then 
subtracted from the ∆CT value of the test sample giving a ∆∆CT value. This value is then 
used to calculate the fold change using the equation 2(- ∆∆CT) (Applied Biosystems, User 
Bulletin 2: Relative Quantitation of Gene Expression). A fold-change of 2 or higher is 
generally considered significant. 
  
Western Blotting: Whole cell extracts were prepared from mammospheres and bulk 
cultured cells. Mammospheres were collected by centrifugation 200 x g for 5 minutes, 
washed one in ice-cold PBS and then lysed with 75 µL-100 µL ice-cold RIPA buffer 
(0.1% Sodium dodecyl sulfate (Sigma), 1% Noniodet P40 (Roche)) containing freshly 
added 0.2% sodium deoxycholate (Sigma). Immediately before protein extraction one-
fourth tablet of Mini complete protease inhibitor cocktail was added to 2.5 ml of 
extraction buffer. Cell monolayers were treated similarly, with the exception that they 
were rinsed with cold PBS and lysed directly on the tissue culture plates. The plates 
were then scraped using a cell lifter (Corning) to collect the cells. The extracts were 
briefly sonicated (three pulses of 3-5 seconds each) using a Fisher Scientific Sonic 
Dismembrator Model 100 (setting 2), and incubated for one hour on ice. The samples 
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were then microcentrifuged for 20 minutes 16,000 x g at 4°C to pellet insoluble protein. 
Samples were stored at -80°C prior to analysis. Protein concentration was quantitated 
using a standard curve method using the Bio-Rad Protein assay reagent (1:5) (Bio-Rad, 
Hercules CA). Briefly, a standard curve was prepared ranging from 0-40 µg/ml, and then 
the protein samples were diluted 1:500 for the quantitation in the assay reagent. 
Quantification was done using the Omega Polar Star plate reader (BMG Labtech) at  
595 nm.  
 
Western blotting was performed using the Invitrogen XCell SureLock Mini-Cell 
Apparatus and the NuPAGE electrophoresis system. Samples were prepared by using 
50 µg of total cellular protein and adding 4X NuPAGE LDS buffer and Milli-Q water for a 
1X final concentration. Samples were run under non-reducing conditions. They were 
vortexed, and heated at 70oC for 10 minutes using an Eppendorf thermomixer 5436. The 
samples were loaded on a NuPAGE Novex 7% Tris-Acetate Gel, covered with NuPAGE 
Tris-Acetate SDS buffer, and run at 150 volts for approximately 1 hour. The proteins 
were then transferred to an Immobulon-P transfer membrane (Millipore). This 
polyvinyldifluoride membrane was first activated by immersion in methanol for 15 
seconds, MilliQ-water for 30 seconds, and soaking in NuPAGE transfer buffer for 5 
minutes. The transfer was performed using the XCell II Blot module with 1X NuPAGE 
transfer buffer for 2 hours at 30 volts. The membrane was then blocked with 5% non-fat 
milk (Bio-Rad) with Tris-buffered saline containing 0.1% Tween for 1 hour at room 
temperature followed by three washes in 1X Tris-buffered saline (25X TBS = 0.5M Tris-
Base, 3.75 M Sodium Chloride, pH = 7.5) with 0.01% Tween (TBST) for 5 minutes each. 
The membrane was then incubated overnight at 4 oC with Hes-1 antibody (ab55265, 
Abcam) (2.5 µg/ml) in 5% milk in TBST. After three washes for 5 minutes each with  
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TBST, a secondary antibody (sheep anti-mouse IgG Horseradish Peroxidase 
linked whole antibody, (GE Healthcare, Piscataway, New Jersey) was added at a 1:3333 
dilution and incubated in 5% in TBST, followed by three washes with TBST. The 
membrane was incubated with Pierce Supersignal Western Dura Extended Duration 
Substrate for 5 minutes and the results recorded using an Intelligent Dark Box LAS-3000 
imager (Fujifilm Tokyo, Japan). β-tubulin (1:7500, Clone B512, Sigma) was used as a 
loading control. Following documentation of the Hes-1 results, the membrane was 
blocked again as described then incubated with the β-tubulin antibody diluted in 5% milk 
for 1 hour at room temperature. The remaining protocol was followed as stated above.  
 
Luciferase Assays: The Hey-1 (also known as HesR1, HERP2, HRT1) luciferase 
reporter construct was the gift of Dr. M. Gessler (University of Wuerzburg, Wuerzburg, 
Germany). Approximately 3 kb of the promoter region (-2839 to +87) of Hey-1 was 
inserted in front of the luciferase gene in the promoterless vector, pLuc. T47D-A18 and 
T47D-C42 cells were plated at 2.5 x 105 cells/ml and 1x106 cells/ml respectively in a 96 
well plate (Corning) in standard media without penicillin-streptomycin. The cells were 
allowed to attach and grow overnight (T47D-A18) or for 48 hours (T47D-C42) to achieve 
approximately 80% confluence. Transfection reactions were prepared using 
Lipofectamine 2000 (Invitrogen) so that each reaction contained ample reagent to 
perform the experiment in quadruplicate. Briefly, 1.25 µg (0.25 µg/well) Hey1-luciferase 
plasmid was added to 125 µl Opti-MEM media (Invitrogen). Next, 6.25 µl of 
Lipofectamine 2000 was added to a separate tube containing 125 µl of Opti-MEM media. 
Following a 5-minute incubation at room temperature, the solutions were mixed together 
and incubated an additional 20 minutes. Fifty microliters of DNA-Lipofectamine solution 
  77  
   
was then added to the cells. Transfected cells were allowed to recover overnight prior to 
removal of the transfection media and subsequent treatments. In these assays, the cells 
were treated with a GSI or DMSO as a control for 24 hours prior to measuring luciferase 
activity using the Steady-Glo Luciferase Assay System (Promega, Madison WI) and a 
Turner Biosystems Veritas microplate luminometer. Following removal of the media, 25 
µl PBS and 25 µl of Steady Glo reagent were added to each well, and the plate 
incubated for 5 minutes to ensure complete cell lysis. The samples were then transferred 
to a 96-well white (Lumitrac) microplate (Bioexpress, Kaysville UT) and read on the 
Veritas microplate luminometer. Transfection efficiency was determined by transfecting 
additional cells that were not treated with a plasmid expressing green fluorescent protein 
(GFP), percent transfection efficiency was determined by flow cytometry, and the 
average value of used to normalize the luciferase data as previously described (238). 
Previous studies from our lab have shown that co-transfection with firefly luciferase and 
renilla luciferase constructs resulted in serious problems with promoter crosstalk 
resulting in uninterpretable data. This is due to the presence of cryptic promoter 
elements in the backbone of the luciferase vector that can alter luciferase gene 
expression under certain conditions. Thus, we were unable to use a dual luciferase 
assay to determine both transfection efficiency and Notch-dependent luciferase activity 
in the same sample. 
 
Determining Notch Activation Using the Notch Decoy: T47D-A18 cells were transfected 
with the Hey-1 luciferase reporter construct in 96 well plates as stated above. The  
following day, LTK cells overexpressing Jag-1 (LTK-Jag-1) were scraped from plates, 
counted and resuspended at 1x106 cells/ml in T47D-A18 media without penicillin-
streptomycin. Fifty microliters of the LTK-Jag-1 cell suspension (or 5 x 104 total cells) 
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was incubated with 3 µM of the recombinant human Notch1-Fc protein or 3 µM 
recombinant human IgG1 Fc protein for 15 minutes, and then added to the transfected 
T47D-A18 cells. The cells were co-cultured for 24 hours prior to determining luciferase 
activity as described above.  
 
Determining Notch activity after transfection of an siNotch-1 plasmid: T47D-A18 cells 
were plated in 10 cm tissue culture plates (Corning) so that they were 70-80% confluent 
(2.5x106 cells/plate) at the time of transfection. They were transfected with 1 µg of 
PLVTHM-siNotch-1, which also contained a GFP coding sequence using 150 µl of 
Lipofectamine 2000 as described above. Cells were passaged the following day. In order 
to achieve high levels of GFP expression cells were analyzed by flow cytometry 48 
hours after transfection. First, cells were trypsinized and collected by centrifugation 200 
x g for 5 minutes then resuspended in mammosphere media at 4x107 cells/ml and FACS 
sorted into GFP-positive and GFP-negative cells. These cells were grown as 
mammospheres under standard conditions.  
 
Proliferation Assay: Mammosphere cultures were established in Corning ultra-low 
attachment 96 well plates by plating 3,200 cells/well (quadruplicate wells for each test 
condition) in the presence or absence of Notch inhibitors (GSIs or Notch decoy) or 
appropriate control reagents as stated above. After 48 hours, an MTT based assay,  
MTS, (3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-
tetrazolium) was performed using the CellTiter96 Aqueous One Solution Cell Proliferation 
Assay (Promega, Madison, WI). To quantitate proliferation 20 µl of reagent was added 
directly to 100 µl of cells/media in culture of media. Absorbance was measured every 
hour for 4 hours on an Omega Polar Star plate reader (BMG Labtech) at 490 nm. 
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Background color development was calculated using wells containing media and 
CellTiter 96 Aqueous One Solution without cells.  
 
Colony Formation Assay: Primary mammosphere cultures were established and treated 
after 24 hours with MRK003 (10-20 µM). After an additional 24 hours, mammospheres 
were dissociated and used in the colony forming assays. A 24 well plate (Corning) was 
prepared by placing 500 µl of 0.5% Noble agar (BD Biosciences) in mammosphere 
media in each well and allowing the agar to solidify for 30 minutes. Single cells from the 
dissociated mammospheres were counted using a hemacytometer and resuspended to 
1.5 x 104 cells/ml. One milliliter of the cell suspension was added to 2 ml of warm 0.5% 
Noble agar in mammosphere media in the presence or absence of MRK003 (10-20 µM) 
or DMSO as a control. Five-hundred microliters of cell-agar suspension (2,500 cells/well) 
was placed on top of the agar-base in the 24 well plate. Plates were incubated at 37°C in 
5% CO2 and were examined every other day for up to 28 days. Every five days, 500 µl of 
fresh media with or without MRK003 or DMSO was added on top of the agar. 
Photographs were taken of 10 random high power fields every seven days to quantitate 
the results.  
 
Annexin V / Propidium Iodide Staining: The ApoScreen Annexin V Apoptosis (Beckman 
Coulter, Brea, CA) kit was used to confirm MRK003 induced apoptosis. Mammospheres 
from T47D-A18 and SKBR3 cell lines were treated with either DMSO or MRK003 (20 
µM) for 4 days and then collected and dissociated as already described. The cells were 
resuspended in 1X binding buffer, and 10 µl of Annexin V added to the samples. The 
samples were incubated for 15 minutes on ice. Two-hundred microliters of binding buffer 
was then added followed by 10 µl of PI. Each experiment included appropriate controls 
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including unstained cells for setting the appropriate gates, and cells stained with only 
Annexin V or PI for compensation controls.  
 
Human Apoptosis RT2 Profiler PCR Array: The human apoptosis RT2 Profiler PCR array 
(SABioscienes) was performed using manufacturer’s instructions. Because the primers 
used in this PCR array do not span exon-exon junctions, contamination of the RNA 
preparation with genomic DNA is a potential issue. Therefore, the RNA samples were 
treated with DNAase (Qiagen) for 10 minutes as described in the RNeasy Mini Kit 
protocol. In addition, the PCR array includes controls that evaluate genomic DNA 
contamination. The RT2 First Strand Kit was used to synthesize cDNA for these studies.  
RNA (1 µg) was treated to eliminate genomic DNA and then cDNA prepared following 
the manufacturer's instructions. The RT2 Real-Time SYBR Green/Rox PCR master mix 
was used for the RT-qPCR steps. SYBR Green mixture was prepared by adding diluted 
2X SA Biosciences RT 2 qPCR Master Mix containing cDNA, and 25 µL of this mixture 
was added to the RT2 Profiler PCR plate provided (which contained primers). Enough 
mixture was prepared for two plates (DMSO and MRK treated cells) and the plates were  
set up simultaneously to eliminate the potential differences that could confound 
interpretation of the assay. The samples were analyzed by Applied Biosystems 7300 
sequence detection system using the following program 95 oC for 10 minutes followed by 
40 cycles of 95 o C for 15 seconds and 60 oC for 1 minute. The data was analyzed by the 
comparative method using the SABiosciences web based data analysis software.  
 
Statistical Analysis: Statistical analysis was performed using a Student’s t-test when 
comparing two populations. A p-value of less than 0.05 was considered significant. 
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CHAPTER 3 
RESULTS 
 
Hypothesis: The putative breast CSC contains elevated levels of activated Notch and 
depends on Notch signaling for self-renewal, survival, and/or proliferation. Notch 
inhibitors may adversely affect this population. 
 
Specific Aim 
Determine the effects of Notch inhibitors on the putative CSC, specifically on self-
renewal, proliferation, and survival. 
 
Identification of Putative Cancer Stem Cell 
Four different methodologies are currently utilized to identify and isolate / enrich 
stem cells: side population (SP) (127), mammosphere formation (128), phenotypic 
markers (129, 130, 145), and aldehyde dehydrogenase-1 (ALDH-1) activity (131). We 
have attempted all four techniques in these studies, and determined that each had its 
own advantages and disadvantages. 
 
Side Population 
We began our studies by isolating the SP from two cell lines, T47D-A18 and 
T47D-C42. These subclones of the T47D cell line were chosen because they represent 
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two of the most common subgroups of breast cancer, ERα-positive (T47D-A18) and 
ERα-negative (T47D-C42). Moreover, because the cell lines possess the same genetic 
background, we hypothesized that we might be able to identify overt differences 
between ERα-positive and ERα-negative stem-like cells, with respect to Notch signaling. 
 
Traditionally, Hoescht 33342 has been the dye used in SP analysis; however, we 
were unable to use it, as we could not obtain adequate fluorescence to discern the SP. 
This is because an ultraviolet laser is required to excite / detect this dye, and we do not 
have one in our core facility (LUMC). As an alternative, we used Vybrant DyeCycle 
Violet (DCV) (lnvitrogen), a vital dye detected with a violet laser that has been effectively 
utilized in SP analysis (135). T47D-A18 or T47D-C42 cells were incubated at 37oC with 
DCV to allow uptake of the dye. The cells were placed on ice, PI added, and then 
analyzed by flow cytometry. Because stem cells should effectively efflux the dye due to 
elevated ABC transporter expression, they are less fluorescent than the bulk population 
and are readily identified in regions of low fluorescence. To confirm that the SP was 
correctly localized, control cell samples were pretreated with verapamil hydrochloride (50 
µM- 100 µM) to block ABC transporter activity. Following treatment with verapamil 
hydrochloride, the stem-like cells cannot efflux the dye and maintain a high level of 
fluorescence. Therefore, the SP will essentially “disappear” on the dotplot used for 
analysis. Figure 7 shows representative data from the two cell lines. Untreated cells 
contained on average 1.4% ± 0.1 SP for T47D-A18 and 1.2% ± 0.2% SP for T47D-C42 
cells. As expected, verapamil hydrochloride treatment reduced the SP to 0.55% ± 0.1% 
(T47D-A18) and 0.6 ± 0.2% (T47D-C42). Similar experiments were performed in MDA-
MB-231 and MCF7 cell lines, but we could not reproducibly identify a SP. Similarly, 
Patrawala et al. tested several breast cancer cell lines and reported no detectable SP in  
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MDA-MB-231 cells and only a 0.2% SP in MCF7 cells (137). 
 
 
 
 
 
 
 
 
 While useful for certain applications, the SP has several disadvantages. First, as 
mentioned above, a SP cannot be reproducibly isolated from all cell lines or cell samples 
despite the detection of stem-like cells via alternative methods. Second, the SP is 
considered stem cell enriched, but is not a pure population. The SP is contiguous with 
the non-SP (Figure 7), and it is not possible to completely separate the two populations. 
Moreover, any cell with low fluorescence, regardless of the reason, will fall into the SP  
 
Figure 7: The side population (SP) can be identified in T47D-A18 and T47D-
C42 cells. Representative dot plots showing the SP in T47D-A18 and T47D-
C42 breast cancer cell lines. As anticipated, the SP consisted of <2% of the 
bulk cell population and could be effectively reduced by pre-treatment with 
the ABC transporter inhibitor, verapamil (p<0.01). Note that the SP fraction 
is contiguous with the non-SP cellular fraction. Therefore, they represent a 
subset of cells enriched for stem-like cells, but are not a pure population. 
Representative data, including the percentage of SP cells, are shown. At 
least 6 independent experiments were performed and averaged data from 
the combined experiments is listed in the text. 
 
  84  
    
region. Given these issues, we utilized SP for only our initial studies. During the course 
of this work, new methods were described and validated, and we moved to these newer, 
more widely accepted methods for the remainder of the studies.  
 
Mammosphere Formation 
Sphere formation assays are the primary means of maintaining stem cells in 
culture. This technique involves culturing bulk tumor cells on ultralow attachment plates 
in specialized serum free media. Since most differentiated cells require attachment to 
survive, these non-adherent culture conditions select for the stem-like and early 
progenitor cells. Initial studies demonstrated that mammosphere formation is a measure 
of stem cell self-renewal, while the size of the mammospheres is a measure of 
progenitor proliferation (128, 241, 242). Dontu et al. found that primary mammosphere 
cultures prepared from normal human breast tissue were enriched for progenitor cells, 
but secondary and later mammosphere cultures consisted almost entirely of early 
progenitor cells (237). They calculated that each mammosphere was composed of 1-2 
stem cells surrounded by bipotent and tripotent progenitors. Based on these studies, we 
primarily used secondary mammospheres for our experiments.  
 
Initial experiments used immunostaining of cytospin cell preparations to confirm 
the mammospheres had a similar cellular composition to those described in the 
literature. We used well-known markers for mammary basal cells (CK-5), luminal cells 
(CK-18, ESA) and myoepithelial cells (CK-14, CD10). Mammospheres derived from 
T47D-A18 cells were found to contain cells that were CK-5-positive (26%), CK-18- 
positive (95%), ESA-positive (95%), and CK-14-positive (20%) (Figure 8). Less than 
10% of the cells were faintly CD10-positive (Figure 8). While staining for T47D-A18 cells 
  85  
    
has not been previously reported, these results are consistent with those published by 
Dontu et al. and Farnie et al. (128, 194). Dontu et al. showed that mammospheres 
derived from reduction mammoplasties were about 50% positive for ESA and few cells 
stained positive for CK-5. Farnie et al. showed that 85% of cells in mammospheres 
derived from DCIS were positive for ESA and about 30% were CK-14 positive, which is 
consistent with Dontu et al. who showed 20% of cells were positive for CK-14 (128, 194). 
From these results, we concluded mammospheres prepared under our experimental 
conditions are similar to those from other laboratories. Differences may be due to the 
different samples that were tested. As a separate approach, the SP and non-SP cells 
from T47D-A18 cells were collected and used to establish mammosphere cultures. 
Spheres only formed in cultures derived from SP cells but not non-SP cells (data not 
shown). This is consistent with previously reports (128). Since these early studies, we 
have successfully prepared mammospheres from numerous cell lines including T47D-
C42, MDA-MB-231, SKBR3, BT474 and MCF7 cells, and four out of six primary samples 
from patients with drug resistant breast cancer pleural effusions. 
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CD44+ / CD24low/- ESA+ 
Breast cancer stem cells were originally identified by Al Hajj et al. based on their 
CD44+CD24low/- Lineage- ESA+ phenotype (129). We used a similar strategy to identify 
CSCs in established cell lines. There was little to no evidence of a CD44+CD24low/- 
population in T47D-A18 (0.7% ± 1.3) or T47D-C42 cells (0% ± 0.08). Even though the 
T47D-A18 cells did, on average, show a reasonable CD44+CD24low/- population, there 
was significant variability between experiments as indicated by the standard error, 
making it impossible to use this method to collect stem-like cells from experiments.  
Figure 8: Mammospheres express various markers associated with 
progenitor, luminal and myoepithelial cells. Mammospheres were positive for 
CK-5, CK-18, ESA and CK-14, which is similar to published reports. CD10 
immunostaining was faint in a small portion of cells. Data are representative of 
at least 3 independent experiments.  
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Sheridan et al. also reported that the parental T47D cell line had 0% CD44+CD24low/- 
cells (144). In contrast, MDA-MB-231 cells consistently showed a vast majority of 
CD44+CD24low/- cells (96.1% ± 2.2). Similarly, published studies have also shown over 
90% of MDA-MB-231 cells are CD44+CD24low/- (144, 145). Further studies by Fillmore 
and Kuperwasser found the tumorigenic subset of MDA-MB-231 cells could only be 
accurately identified if the cells were also evaluated for ESA. They reported 2.5% of 
these cells were CD44+CD24low/- ESA+ (145). Likewise, we found 5.5% ± 1.7 of MDA-MB-
231 cells were CD44+CD24low/- ESA+ under our experimental conditions.  
 
Aldehyde Dehydrogenase-1 Activity (Aldefluor) 
The Aldefluor kit can be used to identify cells with elevated ALDH-1 activity that can then 
be identified and isolated by flow cytometry. We examined a variety of cell lines but 
found little to no evidence of an ALDH-positive population (T47D-A18 (0.33% ± 0.18), 
T47D-C42 (0.133% ± 0.08) and MDA-MB-231 cells (0.0% ± 0.08), even using cell lines 
that were previously reported to have this population (243). We contacted Dr. Gabriela 
Dontu, an author on the initial report, who stated that the FACS-Aria flow cytometer, 
which is available in our core facility, was not useful for these assays using cell lines 
(personal communication). The level of fluorescence in the ALDH-positive population in 
cell lines is substantially less than primary samples necessitating the use of a powerful, 
200 mW argon laser. As the FACS-Aria has only a 40 mW laser, we were unable to use 
this technique for the majority of our experiments. However, we did find a distinct ALDH-
positive population when using primary tumor cells from metastatic breast cancer pleural 
effusion samples.  
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Taken together, we successfully identified the breast cancer stem-like population 
using all four methodologies currently utilized by working with breast CSCs. However, 
significant limitations to each method were found based on the technique itself, the use 
of established cell lines, or lack of access to necessary equipment. As a primary goal of 
our studies was to compare and contrast results between tumor cells derived from 
different subtypes of breast cancer, mammosphere formation became the primary 
methodology used in the studies. Only mammosphere formation consistently enriched 
for the putative CSC in a majority of cultured cell lines and patient samples. This data 
could then be extended using other methodologies to identify and isolated the stem-like 
cells.  
 
Notch Expression and Activation in the Putative Breast Cancer Stem Cell  
Population 
 
Notch Activation/Expression in Side Population versus Non-Side Population 
We began these studies using RT-qPCR to evaluate mRNA expression of Notch 
pathway related genes. First, Notch expression and activation were examined in SP and 
non-SP cells isolated from T47D-A18 and T47D-C42 cell lines. Bulk cultured cells were 
labeled with DCV and the SP and non-SP cells collected using FACS. Total RNA was 
extracted and cDNA synthesized. RT-qPCR was used to determine relative expression 
of Notch-1, Notch-4 and two downstream targets of Notch activation, Hes-1 1and Hey-1. 
This is important because Notch expression does not indicate activation. Therefore, 
expression of downstream targets of Notch are commonly used as surrogate markers of 
activation.  
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Figure 9: Side Population 
cells expresses higher 
mRNA levels of several 
Notch targets and 
receptors compared to 
non-side population cells 
as determined by RT-
qPCR. Combined data 
(average ± standard error 
of the mean (SEM)) from 
at least three independent 
experiments is shown.  
 
The results showed a significant increase in expression of Notch-1, Notch-4, 
Hes-1, and Hey-1 mRNA (p<0.05) in SP derived from T47D-C42 cells compared to non-
SP cells (Figure 9). In contrast, T47D-A18 cells showed a consistent increase in 
expression of these Notch-related genes, but the differences were not statistically 
significant (Figure 9). In both cell lines, no significant difference was observed in 
expression of Hey-L, Hes-5 or Hey-2 mRNA (data not shown), between SP and non-SP 
cells. 
 
 
Notch Expression/Activation in Mammospheres versus Bulk Cells 
To confirm and extend the results, we examined expression of an expanded set 
of Notch-related genes in mammospheres and bulk cultured (monolayer) cells from 
breast cancer cell lines (T47D-A18, T47D-C42, MCF7, MDA-MB-231, MDA-MB468, 
SKBR3, and BT474) as well as a primary tumor sample from a breast cancer pleural 
effusion (termed BC-PE6). To confirm the stem-like nature of the mammospheres, 
Nanog expression was evaluated. This transcription factor is well recognized as an 
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important mediator of stem cell pluripotency and self-renewal (244). 
 Interestingly, Hes-1 mRNA expression was significantly increased in 
mammospheres compared to bulk cells in all tested samples (Figure 10, p<0.05) clearly 
documenting elevated Notch activation in the stem-like and progenitor population in 
breast cancer. Other Notch target genes were also elevated in some, but not all samples 
(Figure 10). With respect to Notch receptors and ligands, the results showed at least one 
receptor and one ligand were elevated in mammospheres compared to bulk cells in each 
sample, although the actual receptor and ligand involved varied. Finally, Nanog was 
significantly upregulated in most of the tested samples, indicating mammospheres 
contained cells with a stem-like phenotype. Nanog was not increased in MDA-MB-231 or 
MDA-MB-468 mammospheres, which may be related to the phenotype of these culture 
adapted cell lines (Figure 10). The fact that spheres from these cell lines did not 
demonstrate increased Nanog expression does not mean that they are not stem-like-
cells as other stem cell related markers such as Oct4 or Sox2 may be elevated.  
 
  91  
    
 
 
 
 
 
 
 
  
Figure 10: Various Notch ligands, receptors and targets are upregulated in 
mammospheres versus bulk cells in breast cancer cell lines and a pleural effusion 
sample. Relative expression of Notch ligands, receptors and downstream targets 
of Notch activation (several members of the Hes and, Hey family of genes and 
Deltex), from seven breast cancer cell lines and one primary breast cancer pleural 
effusion sample (BC-PE6) as determined by RT-qPCR. mRNA expression in bulk 
cultured cells was set at 1.0 and relative mRNA expression in mammospheres 
calculated using the comparative method. The results represent combined data 
(average ± SEM) from three independent experiments where each qPCR assay 
was performed in triplicate. Statistical analysis was performed using a Student’s t-
test where p<0.05 was considered significant. For the primary breast cancer 
pleural effusion sample, data from a single experiment performed in triplicate are 
shown, where the error bars represent the standard deviation within the 
experiment.  
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The results were confirmed at the protein level using Western blot analysis. As a 
large number of mammosphere cultures are required to isolated sufficient protein for 
Western blot, we limited our studies to expression of Hes-1 because it is a surrogate 
marker for Notch activation and was elevated in all mammosphere samples at the 
mRNA level. Figure 11 shows a representative Western blot analyzing proteins isolated 
from bulk and mammosphere cultures from four different cell lines. In each case, 
mammospheres expressed significantly more Hes-1 protein compared to bulk culture 
cells. 
  
 
 
 
 
 
 
 
 
 
Together, these data demonstrate that the Notch pathway is preferentially 
expressed and activated in the stem-like and progenitor cells derived from numerous 
breast cancer cell lines and a primary tumor sample. Moreover, the results were 
relatively consistent between analysis of mammosphere-derived stem-like cells or SP 
cells. We attempted to examine Notch expression and activation in the Aldefluor-positive  
versus Aldefluor-negative population isolated from a primary tumor sample (BC-PE3). 
Although we found Hes-1 (2.1-fold increase) and Nanog (2.7-fold increase) were 
Figure 11: Western blot analysis for Hes-1 expression in mammospheres 
and bulk tumor cells from representative cell lines. The fold increase in 
Hes-1 expression in mammospheres compared to bulk tumor cells was 
calculated using densitometry and is presented at the bottom of the figure. 
Data are representative of 3 independent experiments showing similar 
results. B: bulk tumor cells; MS: mammospheres 
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increased in the Aldefluor-positive population compared to the Aldefluor-negative subset, 
we did not obtain enough RNA to examine the full panel of Notch related genes. 
Unfortunately, we were unable to examine additional primary specimens as we could not 
obtain more patient material.  
 
The Effects of Notch Inhibition on the Putative Cancer Stem Cell Population 
Given the elevated levels of Notch expression and activation consistently found 
in the breast cancer stem-like population, we examined the effects of Notch inhibition on 
the cells. Initial studies used three structurally distinct GSIs to inhibit Notch signaling: 
LLNIe, LY-411,575 and MRK003. We began our work with LLNle, a tripeptide, aldehyde-
containing GSI, because of its potent inhibition of γ-secretase activity and its availability 
from commercial sources. However, LLNle has been shown to inhibit serine proteases 
when used at concentrations over 5 -10 µM in breast cancer cell lines (Dr. L. Miele, 
unpublished data). While we used this GSI at concentrations (0.5 - 1 µM) well below this 
range, we confirmed the data with two additional GSIs, LY-411,575 and MRK003 (174, 
234). These GSIs do not contain the aldehyde group responsible for protease inhibition 
and this effect was not reported for these two GSIs.  
 
Measuring Notch Activity in the Presence of Gamma-Secretase Inhibitors 
To determine the optimal concentration of each GSI for our experiments, we 
performed a Iuciferase reporter assay. We selected a pGL3 basic-based reporter 
construct where luciferase gene expression was driven by the 3-kb promoter region of 
the Hey-1 gene. T47D-C42 and T47-A18 cells were transfected with the plasmid using 
Lipofectamine 2000, treated with increasing GSI concentrations, and luciferase 
expression evaluated after 24 hours. Figure 12 shows a significant reduction in 
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luciferase expression in GSI-treated cells compared to control (DMSO)-treated cells. 
Specifically, luciferase activity was decreased by 6.7-fold for 0.5 µM LLNIe, 3.0-fold with 
25 µM LY-411,575, and 5.6-fold with 10 µM MRK003 (Figure 12). 
 
 
 
 
 
 
 
 
We confirmed the downregulation of Notch activity following MRK003 treatment 
using RT-qPCR for Hes-1 mRNA. Mammospheres derived from T47D-A18 cells and 
treated for 24 hours with 20 µM MRK003 showed a 16-fold decrease in Hes-1 mRNA 
expression compared to DMSO-treated controls (Figure 12B). 
 
Figure 12: Gamma-Secretase-
Inhibitors decrease Notch 
activation. (A). GSIs effectively 
block Notch activation as 
determined by a Notch-
responsive luciferase reporter 
construct. Although baseline 
Notch activation was modest, a 
significant reduction in luciferase 
activity was noted. Results 
represent combined data 
(average ± SEM) from 2 
experiments performed in 
triplicate. Similar results were 
noted for T47D-A18. LLNle = Z-
Leucine-Leucine-Norleucine-
CHO, LY = LY411, 575, MRK = 
MRK003, RLU= relative 
luciferase units. (B). MRK003 
significantly blocked Notch 
activation in treated 
mammospheres compared to 
control-treated spheres as 
determined by Hes-1 mRNA 
expression. Results are 
representative of two 
independent experiments 
performed in triplicate. Error bars 
represent SEM between 
replicates.  
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Gamma Secretase Inhibitors Decrease the Side Population 
We began these studies by examining the effect of GSIs on SP analysis. Bulk 
T47D-A18 and T47D-C42 cells were treated with one of the three GSIs and after 24 
hours, the cells were loaded with DCV with or without verapamil treatment and analyzed 
by flow cytometry. Verapamil treated cells were used to confirm the correct cell 
population had been identified on flow cytometry. Figure 13 shows that all three GSIs 
significantly decreased the SP compared to the DMSO control-treated cells. This data 
indicates Notch signaling may be required for maintenance of the SP.  
 
 
 
 
 
 
 
 
 
 
 
 
Gamma Secretase Inhibitors Prevent Mammosphere Formation  
 While informative, SP analysis could only be performed with a limited number of 
cell lines. Therefore, we turned to mammosphere formation assays as our primary 
method for examining the effects of GSIs on the putative CSC. Mammosphere cultures 
were established from various breast cancer cell lines and primary patient samples. 
Figure 13: Gamma-Secretase 
Inhibitors reduce the SP in 
different cell lines. T47D-C42 
cells were treated with DMSO 
(control), LLNle (0.5 µM), 
MRK003 (10 µM) or LY-
411,575 (25 µM) and analyzed 
on flow cytometry for the SP. 
Each GSI significantly reduced 
the percentage of cells in the 
SP. Similar results were found 
with T47D-A18 cells, although 
slightly higher concentrations of 
MRK003 (20 µM) and LY-
411,575 (50 µM) were required. 
The results represent combined 
data (average ± SEM) from 3-5 
independent experiments. 
Statistical analysis was 
performed using a Student’s t-
test.   LY = LY,411,575 and 
MRK= MRK003 
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Once small spheres or cell clusters formed, the cultures were treated overnight with GSI, 
the spheres dissociated, and new mammosphere cultures established in the presence or 
absence of fresh drug. After two days, small spheres were evident in DMSO-treated 
samples (Figure 14A), while treatment with any of the GSIs revealed primarily single 
cells (Figure 14B, and data not shown).  
 
Treatment of the stem-like and progenitor cells from T47D-A18 and T47D-C42 
cells with LLNle or LY-411,575 initially blocked mammosphere formation (Figure 14B), 
but at 5 days after treatment, cell clusters were clearly re-forming in the GSI-treated 
samples indicating a reversible or temporary growth arrest (data not shown). In contrast, 
T47D-A18 and T47D-C42 derived mammospheres treated with MRK003 remained as 
single cells until 6 - 7 days after treatment when the cultures appeared to contain 
primarily debris and a condensed or fragmented cellular morphology (Figure 14C). No 
evidence of sphere formation was found in the MRK003-treated cultures even after 
continued culture for an extended period of time (12 days), or addition of fresh growth 
media (data not shown). It should be noted that while 10 µM or 20 µM of MRK003 were 
generally used, similar results were obtained with 5 µM MRK003; however, it took longer 
for cells to reach the phenotype seen in figure 14C (approximately 10 days) (data not 
shown).  
 
We extended our studies using MRK003 GSI to additional breast cancer cells 
lines MDA-MB-231, MCF7, SKBR3, BT474, and six primary breast cancer pleural 
effusion samples (Figure 14D-G). Only four of the six primary samples formed 
mammospheres in culture making it impossible to evaluate the other two. Strikingly, in 
each breast cancer cell line and the four patient samples, MRK003 abolished 
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mammosphere formation resulting in cultures of fragmented, condensed cells and debris 
after 7 days (figure 14C and data not shown). The results were similar for ERα-positive 
(T47D-A18, MCF7), ERα-negative (MDA-MB-231, T47D-C42, MDA-MB-468), and 
Her2/neu-positive (SKBR3, BT474) cell lines as well as 4 of 6 patient samples (3 
recurrent , ERα-positive and one triple negative pleural effusions) (Figure 14D-G).  
 
 
 
 
 
 
 
 
 
 
Figure 14: Gamma-Secretase-Inhibitors prevent mammosphere formation in 
various cell lines and breast cancer pleural effusion samples. Secondary T47D-
A18 mammosphere cultures were treated with 20 µM MRK003 or DMSO, and 
were observed for 7 days. (A) DMSO-treatment, 48 hours (insert shows a large 
mammosphere at day 7) (B) MRK003, 48 hours (C) MRK003, 7 days. Cultures 
were treated with the lowest GSI concentrations shown to effectively block 
Notch signaling in reporter assays (LLNle: 0.5 µM, LY-411,575: 25-50 µM, 
MRK003: 10-20 µM). Quantitation was performed by counting sphere-like 
structures. (D). Representative pictures showing mammospheres from different 
cell lines treated with 10 µM MRK003 and pictures taken on day 6. (E). 
Counting sphere-like structures in T47D-A18 and T47D-C42 after treatment with 
one of three GSIs. (F). Counting sphere like structures treated with MRK003 in 
various cell lines (MCF7, MDA-MB-231, BT474 and SKBR3 cells). (G). 
Treatment of two breast cancer pleural effusion samples with MRK003. 
Combined data (average ± SEM) from 3 assays are shown, except for patient 
samples, which are from single assays (hence, there are no error bars). A 
Student’s t-test was used for statistical analysis. *p<0.05. D2: day 2; D7: day 7; 
LY: LY-411,575; MRK: MRK003; BC-PE1 (3), breast cancer pleural effusion #1, 
#3.  
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We next examined proliferation of the stem-like and progenitor cells treated with 
MRK003 or DMSO as a control using an MTT-based assay (MTS assay). Cell 
proliferation was significantly decreased after 48 hours (data not shown). 
  
Notch-1 Fc Chimera Prevents Mammosphere Formation 
The γ-secretase complex is involved in intramembranous cleavage of a number 
of important targets in addition to Notch, such as E-cadherin, CD44 and ERBB4 (186). 
Therefore, we wanted to use a different approach for inhibiting the Notch pathway. The 
Notch-1 Fc chimera (Notch-1 decoy) has been shown to bind Jag-1 and block Notch 
activation. This decoy consists of amino acids 19 – 526 of the Notch-1 extracellular 
domain (including the first 13 EGF repeats) fused to the Fc region of human IgG1. EGF 
repeats 11 and 12 of the decoy will bind to the ligand Jag-1 preventing the interaction 
between endogenous Jag-1 and the Notch receptor. A recombinant human IgG1 Fc 
protein was used as a control.  
 
First, functional activity of the decoy in inhibiting Notch signaling was confirmed 
using a luciferase reporter assay similar to that already described. However, in these 
experiments, we co-cultured the T47D-A18 cells transfected with the Hey-1 promoter 
luciferase reporter construct with cells overexpressing Jag-1 to induce Notch activation. 
Briefly, LTK-Jag-1 (mouse L cells with a deleted thymidine kinase overexpressing Jag-1) 
were pre-treated with the Notch decoy (hN1-Fc) (3 µM) or hIg-Fc (3 µM) control for 15 
minutes before adding them to T47D-A18 cells transfected with the luciferase reporter 
driven by Hey-1 described earlier. Twenty-four hours later the luciferase assay was 
done. There was a significant decrease in luciferase activity in the T47D-A18 cells 
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cultured with the decoy treated LTK-Jag-1 cells demonstrating Notch signaling was 
inhibited (Figure 15).  
 
 
 
 
To examine the effect of the decoy on sphere formation, established 
mammospheres were dissociated, and re-plated in the presence of hN1-Fc (3 µM) or 
hIg-Fc (3 µM). Twenty-four hours later, cultures were evaluated for sphere formation. 
Figure 16A shows two independent experiments using T47D-C42 cells. Both the 
untreated and hIg-Fc treated resulted in formation of small sphere-like cell clusters 
whereas the Notch-1 decoy (hN1-Fc) showed primarily single cells. While all spheres 
were not eliminated by the Notch-1 decoy (11.7±1.3 spheres with hN1-Fc compared to 
25.9 ± 4.7 with hIg-Fc p<0.05), the results showed a reduction in sphere formation 
(Figure 16B). The results were extended using an MTS assay to evaluate proliferation 
following treatment with the Notch-1 decoy, which showed a decrease in the proliferation  
of stem-like and progenitor cells in the presence of the Notch decoy compared to the 
control hIg-Fc protein (Figure 16C). 
Figure 15: A Notch decoy protein reduces Notch activation. T47D-A18 cells 
transfected with a Hey1-luciferase construct were co-cultured with LTK-Jag-
1 cells that had been pretreated with a human Notch-1 Fc chimera (hN1-Fc) 
or human IgG Fc (hIgG Fc) as a control. Luciferase activity was significantly 
decreased by the Notch decoy but not the control protein.   
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Transfection with an siNotch-1 Plasmid Inhibits Mammosphere Formation 
 The results were confirmed by using a short interfering RNA (siRNA) against 
Notch-1 to specifically inhibit Notch-1 expression. The siNotch-1 plasmid, which contains 
a GFP marker, was transfected into T47D-A18 cells using Lipofectamine 2000. 
Knockdown of Notch was confirmed by Western blotting at various time points (Figure 
Figure 16: The Notch 
decoy protein inhibits 
mammosphere 
formation and 
proliferation in T47D-
C42 cells. (A). 
Representative pictures 
show mammosphere 
formation 24 hours after 
treatment with 3 µM hIg-
Fc, but when treated 
with 3 µM hN1-Fc. (B). 
Quantitation of 
mammospheres. Data 
shown are from two 
experiments ± standard 
deviation (SD). (C). An 
MTS assay revealed a 
significant decrease in 
proliferation of cells 
treated with the Notch 
decoy (3 µM) compared 
to the control (3 µM). 
Data shown are from 
two independent 
experiments ± SD. 
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17A). We found that the best inhibition of Notch occurred at 96 hours. In a separate 
experiment, transfected cells were FACS sorted for GFP-positive and GFP-negative 
cells then plated as mammospheres. Cells that did not express GFP (indicating the cell 
did not contain siNotch-1 grew into mammospheres (Figure 17B) while GFP-positive 
cells which were successfully transfected with siNotch-1 remained mainly as single cells 
(Figure 17B). This suggests that Notch-1 was specifically involved in mammosphere 
proliferation.  
 
 
 
Figure 17: Transfection of the 
siNotch plasmid prevents 
mammosphere formation in 
T47D-A18 cells (A) 
Transfection of a siNotch-1 
plasmid decreases Notch 
expression in T47D-A18 cells 
as determined by Western 
Blotting. (B) In a separate 
experiment T47D-A18 cells 
were transfected with siNotch-
1-GFP and sorted for GFP-
positive and GFP-negative cells 
after two days. The cells were 
plated under mammosphere 
conditions and monitored for 
mammosphere growth. The 
GFP-negative cells (not 
successfully transfected with 
the plasmid) grew as 
mammospheres (fluorescent 
microscopy on the left side and 
brightfield microscopy on the 
right side). However, cells that 
were transfected with siNotch-1 
(GFP-positive) remained as 
single cells. Representative 
pictures are shown. 
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MRK003 Prevents Colony Formation 
 Many drugs are less effective in vivo or when cells are grown as three-
dimensional spheres in a matrix, which more closely mimics in vivo conditions. 
Therefore, we wanted to determine the effects of MRK003 on cells cultured in soft agar. 
Established mammospheres were prepared, dissociated, and re-plated in 0.35% soft 
agar containing 20 µM MRK003 or DMSO as a control. Experiments were performed 
with T47D-A18, MCF7, MDA-MB-231, and BT474. In every cell line tested, colonies  
were clearly visible in cultures treated with DMSO by day 14, while only cellular debris 
was present in MRK-treated cultures at the same time point (Figure 18). The number of 
colonies was quantified, and there was a statistically significant reduction in the number 
of colonies between control-treated and MRK003-treated cultures in each tested cell line 
(p<0.05). Colony formation assays were attempted with two samples from breast cancer 
pleural effusions; however, there was no colony formation in untreated or DMSO treated 
samples after 21 days making it impossible to draw meaningful conclusions. 
 
 
 
 
Figure 18: MRK003 prevents colony formation in soft agar. Mammosphere 
cultures were established in soft agar in the presence of DMSO or MRK003 (10-
20 µM). DMSO-treated cells formed colonies, which were not visible in MRK003-
treated cultures. Representative results from day 14 are shown. Quantitation of 
colony formation is shown in the bar graph. The results represent combined data 
(average ± SEM) from 3 independent experiments. A Student’s t-test was used 
for statistical analysis *p<0.05.  
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MRK003 Induces Apoptosis in Mammospheres 
As noted above, MRK003 treatment results in cultures containing debris and 
condensed, fragmented cells (Figure 14A-C). To determine if the cells had died via 
apoptosis, we performed TUNEL staining to detect the DNA strand breaks characteristic 
of apoptosis. T47D-A18 mammospheres were treated with MRK003 or DMSO for 24 or 
48 hours and cytospin cell preparations made. Earlier time points were chosen so that 
any positive TUNEL staining could be detected prior to loss of the cell structure at day 7 
(Figure 14C). TUNEL staining showed small mammospheres in the DMSO-treated 
cultures that were primarily TUNEL-negative. However, cells from MRK003-treated 
cultures were primarily single cells with clear evidence of TUNEL-positivity at 24 hours 
that increased at 48 hours (Figure 19). 
 
 
 
 
 
 
 
 
A B C 
Figure 19: MRK003 induces apoptosis in T47D-A18 mammospheres 
(A) DMSO-treated cells (B) MRK003-treated cells at 24 hours (C) 
MRK003-treated cells at 48 hours. Results are representative of three 
independent experiments. Arrows indicate examples of TUNEL 
positive cells.  
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Apoptosis in mammospheres was confirmed using Annexin V / PI staining. 
Annexin V identifies cells in earlier stages of apoptosis by binding to phosphatidylserine, 
which is normally found inside the cell but flips to the outside during early apoptosis. PI 
stains cellular DNA. As the cells in this protocol are not permeabilized, only injured / 
destroyed cells or those in late apoptosis will be PI-positive. Using mammospheres 
derived from T47D-A18 cells and treated for 96 hours with 20 µM MRK003, we found 
64.63% ± 9.32 (p<0.02) of cells were Annexin V-positive (Figure 20). The results were 
confirmed with mammospheres derived from SKBR3 cells, which showed 37.64% ± 6.4 
(p<0.04) of the cells were Annexin V-positive (Figure 20).  
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Figure 20: MRK003 induces apoptosis in T47D-A18 and SKBR3 mammospheres 
as determined by Annexin V / PI staining. (A) Annexin V / PI staining where the X-
axis represent Annexin V and the Y-axis represent PI staining. Representative 
results with SKBR3 are shown. (B) Representative results with T47D-A18 cells. 
(C) Combined data from three independent experiments. Data is presented as the 
average +/- SEM. *<0.04, ** p<0.02. 
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 The Tumor Necrosis Factor-Alpha Pathway may be Involved in MRK003-induced  
Apoptosis 
  The mechanism of apoptosis induced by MRK003 in T47D-A18 mammospheres 
was further elucidated. We chose to use the Human Apoptosis RT2 Profiler PCR array, 
as it provides information on 84 apoptosis-related genes in a single experiment. RNA 
was extracted from T47D-A18 mammospheres treated with MRK003 (or DMSO) for 24 
hours, and RT-qPCR was performed according to manufacturer’s protocol. The raw data 
was uploaded to a web-based analysis program from the array manufacturer that 
calculated the fold change in gene expression between the DMSO and MRK-treated 
samples.  
 
 The data show significant increases in several target genes. Of interest was the 
notable increase in mRNA expression of genes associated with the extrinsic apoptotic 
pathway in MRK-treated mammospheres compared to DMSO-treated controls. The 
targets and fold changes of various targets that were upregulated or downregulated are 
shown in Table 5. Importantly, members of the TNF-receptor family were increased, as 
were several caspases. A DNA damage induced gene, GADD45, was also upregulated 
compared to the DMSO control. Several genes were also downregulated after treatment 
with MRK003. Akt, which plays an important role in cell survival, and Bcl2, a pro-survival 
gene, were downregulated. Caspase-2 was also lower in the MRK003 treated 
mammospheres. Alternate names for the upregulated targets are summarized in Table 
6.  
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Table 5: Summary of tumor necrosis factor-alpha related apoptotic genes 
induced following treatment of T47D-A18 mammospheres with 20 µM MRK003 
for 24 hours. The table shows the average fold-increased/decrease calculated 
by SABiosciences web-based software from 2-3 independent experiments.  
 
 
 
 
 
 
 
 
 
Table 6: Alternate names for apoptotic targets upregulated in the T47D-A18 cell line 
after treatment with MRK003. The table provides only a few alternate names and is 
not comprehensive. 
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c-Jun-N-terminal Kinase and p38 Mitogen Activated Protien Kinase Inhibitors Rescue  
 Mammospheres from the Effects of MRK003 Treatment 
    
 To complement the data gained from the PCR array experiments, we used an 
alternative approach to determine if signaling pathways such as JNK, p38 MAPK, ERK 
(extracellular signal-regulated kinase) or JAK (Janus kinase) were involved. T47D-A18 
mammospheres were treated with either 10 µM MRK003 alone or in combination with 
one of the following inhibitors: JNK inhibitor II, SB203580 (p38-MAPK inhibitor), 
PD98059 (MEK inhibitor) or AG490 (JAK inhibitor). Previous data in the lab showed that 
the functional activity of the inhibitors at 1X and 10X demonstrated substantial blockade 
of the target (240).  
 
 After 24-48 hours, the number of mammospheres present in each condition was 
quantified. The data was analyzed at a time point when clear mammospheres were 
present in the DMSO control. We observed that only the JNK inhibitor 0.040 µM (1X 
concentration) and SB203580 (0.60 µM) (1X concentration) were able to rescue 
mammospheres from MRK003-induced effects (Figure 21 A, B). The other two inhibitors 
did not show mammosphere formation in MRK003 and inhibitor treated wells (Figure 
21C and data not shown). The fact that the JNK inhibitor rescued cells from MRK003 
induced effects supports data shown in Table 4, which shows an upregulation in 
GADD45. GADD45, has been shown to induce JNK-mediated apoptosis (222). An NF-
κB inhibitor and a MEK inhibitor (PD98059) (data not shown) were also tested; neither 
rescued mammospheres from MRK003 induced effects. In fact, at 2X and 10X IC50 
concentrations the NF-κB inhibitor alone blocked mammosphere formation. This would 
indicate that the inhibitor might be having an effect on mammosphere formation which is 
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consistent with published data (245). Such an effect was not seen with any of the other 
inhibitor.  
 
  
Figure 21: c-Jun-N-terminal kinase and p38 mitogen activated protein kinase 
inhibitors resuceu mammospheres from MRK003 effects. Mammospheres 
were treated with 1X or 10x IC50 values of JNK inhibitor II (A), SB203580 (B), 
p38 MAPK inhibitor, or (C) AG490 (JAK inhibitor) for 24 hours. The results 
show the average ± SEM from 4 independent experiments with the exception 
of AG490, which is average ± SD from two experiments. Statistical analysis 
was performed using a Student's t-test. 
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CHAPTER 4 
DISCUSSION 
 
In the last decade, strong evidence has emerged validating the existence of 
breast CSCs and indicates that breast cancer originates from and is maintained by 
CSCs (112). The CSC hypothesis has changed the way investigators are approaching 
development of novel therapies. CSCs are more resistant to radiation and 
chemotherapy, and the development of new therapies targeting these cells is essential 
to the eradication of breast cancer (146, 147).  
 
One way to discover potential targets for the elimination of CSCs is to identify genes that 
are differentially expressed in the putative CSC. A gene signature was recently prepared 
for CD44+ CD24low/- and mammospheres from primary tumors, and the results compared 
to known gene expression profiles of the different breast cancer subtypes (246). The 
CSC pattern most closely resembled the claudin-low phenotype. This may explain why 
these types of cancer are the hardest to eliminate since they contain gene expression 
patterns of the stem-like population (246). In another study using a genomics-proteomics 
approach, the gene expression patterns of CD44+CD24low/- and the different molecular 
classifications of breast cancer were compared. It was found that metaplastic breast 
cancer (claudin-low) had a high ratio of CD44 to CD24. In addition, the CD44+ CD24low/ 
genomic profile correlated with the metaplastic breast cancer and claudin-low profiles 
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(75). This indicates that these cancers express high levels of genes associated with the 
stem-like phenotype.  
 
Shipitsin et al. identified a molecular signature for CD44-positive and CD24-
positive cells derived from breast cancer pleural effusion samples, invasive tumors, 
ascites samples or normal breast tissue (247). They found that CD44-positive cells 
expressed high levels of stem cell markers. In addition, CD44-positive cells preferentially 
expressed genes associated with migration and angiogenesis including vascular 
endothelial growth factor, TGF-β, NF-κB, and members of the Notch pathway. TGF-β 
has been implicated in regulating the pluripotency of human embryonic stem cells 
tumorigenesis and metastasis while vascular endothelial growth factor is important in 
angiogenesis (248-251).  
 
 Using SP analysis, we found increased Notch-1, Notch-4, Hes-1, and Hey-1 
expression in the T47D-A18 and T47D-C42 cell lines. Interestingly, T47D-C42 cells 
showed higher levels of Notch and target gene expression compared to T47D-A18 cells. 
This finding is consistent with studies by Rizzo et al. using bulk-cultured cells suggesting 
that ERα-negative breast cancer cells possessed higher levels of Notch signaling than 
ERα-positive cells (183). This is also consistent with literature which showed that 
elevated levels of Notch were observed in the SP of MDA-MB-453 cells (a HER2 
overexpressing ERα-negative cell line) compared to non-SP cells (252). In another 
study, primary mammary epithelial cell cultures were prepared from mouse mammary 
glands, then stained with Hoescht dye and the SP vs. non-SP analyzed for various  
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targets. It was found that SP cells contained higher levels of the Notch target Hey-1 and 
higher expression of ABCG2 was reported compared to the non-SP. Other Notch targets 
were not explored (253). This is consistent with our data. On the other hand, Patrawala 
et al. tested several cell lines from different cancers, and found that cells that were 
ABCG2-negative (by RT-PCR) expressed higher levels of Notch-1. They also showed 
that for most of the cancers tested the ABCG2-negative population expressed higher 
levels of Oct4, a stem cell marker. However, in breast cancer, the ABCG2-positive cells 
(SP) contained slightly higher levels of Oct4 as compared to ABCG2-negative cells 
(137). Although Patrawala’s results appear contradictory to our data, their study showed 
Notch expression in only one breast cancer cell line (MDA-MB-435), and they did not 
analyze downstream targets of Notch making in impossible to draw conclusions 
regarding Notch activation.  
 
Our studies examining Notch expression and activation in mammosphere-
derived stem-like cells appear to further support this finding. Notch-1 and Jag-1 mRNA 
was increased in mammospheres derived from all tested ERα-negative breast cancer 
cell lines (T47D-C42, MDA-MB-231, MDA-MB-468 cells) compared to spheres derived 
from either ERα-positive cell line (T47D-A18, MCF7). These results are particularly 
interesting given that elevated Notch-1 and Jag-1 expression are known to predict 
outcome in breast cancer (178, 179, 254). Other Notch receptors, ligands, and targets 
were increased in some ERα-negative cell lines, but not others when compared to the 
ERα-positive lines. This was not unexpected in these culture adapted cells as Notch 
signaling is highly context dependent, meaning factors such as the Notch ligand and  
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receptor involved, expression levels of the receptor and ligand, and the cell type in which 
they are expressed affect the outcome of Notch activation (174, 255). Ultimately, studies 
examining a larger number samples, including patient samples that are not culture 
adapted, will be essential prior to drawing definitive conclusions.  
 
Interestingly, members of the Notch pathway have been upregulated in several 
different stem-like populations. Several authors have showed elevated levels of Notch-3 
in mammospheres and the CD44-positive population derived from primary samples. 
Dontu et al. found high levels of Notch-3 in mammospheres derived from reduction 
mammoplasties (128). Sansone et al. found Notch-3 was important in mammosphere 
proliferation (198). Finally, Shipitsin et al. showed that the CD44-positive population had 
slightly elevated levels of Notch-3 compared to the CD24-postive population (247). Our 
data shows that mammospheres derived several breast cancer cell lines (T47D-C42, 
T47D-A18, MDA-MB-231, SKBR3 and BT474) and a breast cancer pleural effusion (BC-
PE6) had upregulation of Notch-3 mRNA compared to the bulk population. However, at 
most a 2.6-fold (T47D-C42) increase in Notch-3 expression was observed in 
mammospheres derived from this cell line. Recently, Harrison et al showed that the 
CD44+ CD24low ESA+ breast CSC population expressed higher levels of activated Notch-
4 than other populations with these markers. These results were verified in MCF7, MDA-
MB-231 and a primary sample. Interestingly, levels of activated Notch-1 were lower in 
the breast CSC population compared to the other populations. The authors provide 
interesting data, which suggests that alternate targets may be necessary depending on 
how the CSC is identified (256).    
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 Our report is the first to demonstrate that a GSI can induce apoptosis in breast 
cancer stem-like cells. Our results with LLNle and LY-411,575 demonstrated temporary 
inhibition of mammosphere formation and growth arrest in the stem-like cells. Notch-1 
siRNA and a Notch decoy also decreased mammosphere formation indicating that Notch 
inhibition was responsible for the observed affects. These findings were consistent with 
published results from other investigators (194, 242). In contrast, we found MRK003 
induced apoptosis. This novel finding is potentially important because GSIs are currently 
in development by several pharmaceutical companies, and Merck Pharmaceutical has a 
drug with similar activity to MRK003 currently in clinical trials for breast cancer. 
  
It is unclear why this compound induced apoptosis, while the other compounds 
had a temporary effect. We hypothesize that MRK003 has increased potency, solubility 
and stability compared to other commonly used GSIs. LY-411,575 is a highly potent GSI, 
particularly for in vivo experiments. In tissue culture, however, it precipitates when added 
to media making it difficult to determine the actual drug concentration reaching the cells. 
Moreover, it has a published half-life in vivo of 2 hours (257). Previous studies in our lab 
re-supplemented LY-411,575 every 6-8 hours (187, 189). Because each addition of LY-
411,575 also adds DMSO to the media, we rapidly reached toxic levels of DMSO using 
this experimental design. LLNle is a commercially available tripeptide containing an 
aldehyde group. The aldehyde group interacts covalently with the active site of γ-
secretase; therefore, once LLNle is bound to the active site, gamma secretase will not 
regain function. Yet, peptides like LLNle, are rapidly degraded in serum, plasma and 
cells, and aldehyde-containing compounds tend to have poor metabolic stability (258).  
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 Other investigators have primarily utilized the GSI N-[N-(3,5-difluorophenacetyl-
L-alanyl)]-S-phenylglycine tert-butyl ester (DAPT). This peptide likely has comparable 
stability to LLNle as it is structurally similar. DAPT has a peak absorbance at 244nm on 
UV spectrometry. Liao et al. recently used DAPT and other peptidomimetics in a series 
of experiments and monitored changes in OD244 as a measure of conformational integrity 
and chemical stability of the compounds (259). They showed that the OD244 of DAPT 
decreased by 50 and 70% after 4 and 24 hours, respectively, of incubation at room 
temperature (259). In contrast, MRK003 has been reported to maintain activity in culture 
for up to 96 hours. Although we cannot rule out that an off-target affect of MRK003 is 
responsible for these results, it is equally plausible that MRK003 is able to more 
effectively inhibit Notch signaling for extended periods.  
 
 It is currently believed that combined therapeutic approaches will be necessary to 
effectively eliminate cancer. This approach has the advantage of targeting cancer cells 
based on different criteria. For example, taxanes can be used to block mitosis targeting 
rapidly proliferating cells along with an alkylating agent to damage DNA or bortezomib to 
inhibit the proteosome. Additionally, synergistic activity between different therapeutics 
may allow lower doses of the individual drugs to be used, which can minimize or even 
eliminate toxic side effects. Therefore, by combining MRK003 with a chemotherapeutic 
agent such as Paclitaxel, Adriamycin, Cytoxan or Taxotere, we may be able to decrease 
the doses and side effects of both drugs in patients. These drugs are commonly used in 
the clinic to treat breast cancer. Paclitaxel may be a good option because the ER status 
of the stem-like population is controversial. Several studies have shown that the stem- 
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like population (as the SP) is ERα-positive (136, 260). Other groups reported an ERα-
negative SP in either mice or humans (261, 262). Additionally, mammospheres likely 
contain both ERα-positive and ERα-negative cells. In order to avoid any complications 
with regard to the ER, using chemotherapeutic agents such as those listed above, which 
are not dependant on the ER should prove beneficial. In fact, Dr. Jenny Chang 
presented recent data from her laboratory, in which breast tumors were established in 
mouse xenografts; once a tumor had grown to 150 mm3-300 mm3 treatment was given in 
the form of Docetaxel, MRK003 or a combination of the two. Their data showed that 
MRK003 was able to decrease the CD44+/CD24low/- population, the Aldefluor-positive 
population, and led to a decrease in mammosphere formation in vitro. Furthermore, 
patients treated with GSI alone or in combination with Docetaxel resulted in their tumors 
containing lower levels of the stem-like population after treatment. Importantly, the tumor 
volume did not decrease in the mouse models, but the level of stem-like cells was 
decreased (263).  
 
Our data suggest that the extrinsic pathway is involved in MRK003-induced 
apoptosis in mammospheres. We found TNF, TNF-R1, caspase 8 and caspase 10 
mRNAs were upregulated in MRK003-treated mammospheres compared to DMSO 
control-treated spheres. TNF-TNF-R signaling is known to induce NF-κB and JNK 
signaling in addition to activating caspases 8 and 10. Moreover, studies have shown 
TNF-R1 is upregulated in stromal cells of breast tumors but not in normal breast tissue in 
a majority of samples (264). Further studies are required to determine if the MRK003-
induced apoptosis can be reversed through blockade of the TNF death receptor  
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pathway. It is less likely that the Fas / FasL or TRAIL death pathways are involved in 
apoptosis induced by the MRK GSI. Although FASL mRNA was induced, Fas expression 
was not altered. Similarly, TRAIL-R1 and TRAIL-R2 mRNAs were induced, but TRAIL 
mRNA was significantly decreased. Without expression of both the receptor and ligands, 
it is unlikely that these pathways play a substantial role in our system.  
 
However, the induction of TRAIL-R1 and TRAIL-R2 remain intriguing as it may 
be possible to harness this death receptor pathway to augment cell killing induced by 
MRK003 GSI. The development of agents that engage TRAIL receptors and induce 
apoptosis has been an area of intensive research. TRAIL has been shown to selectively 
induce apoptosis in tumor cells while normal cells are relatively resistant to TRAIL-
induced death (265, 266). Studies in breast cancer cell lines have shown treatment with 
TRAIL alone induced apoptosis in only 2 out of 16 breast cancer cell lines tested. 
However, by adding chemotherapeutic agents such as doxorubicin or 5-fluorouracil 
along with TRAIL, apoptosis was induced in all 16 breast cancer cell lines (267). The 
reason for this may be that certain chemotherapeutic agents may induce the expression 
of DR4, or DR5 making cells sensitive to TRAIL. It has also been shown that the TRAIL 
receptors had missense mutations in several breast cancer cell lines making them 
unresponsive to treatment with TRAIL (212). An alternative approach would be using 
TRAIL gene therapy. This therapy has been shown to be effective in cell lines that did 
not respond to treatment with TRAIL. An adenoviral vector, which contains the TRAIL 
gene driven by a human telomerase reverse transcriptase promoter is injected into the 
tumor in mouse xenografts. Data showed that after this therapy, there was a complete  
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regression of tumors in 50% of mice and tumors did not re-form for the 5 months that 
mice were monitored after complete regression was observed. This provides strong 
evidence that such a treatment could be effective (268, 269). Clinical trials have also 
been initiated with TRAIL receptor agonists, which showed to be effective against solid 
tumors, but data were preliminary. Additionally, humanized monoclonal antibodies 
against TRAIL-R1 and TRAIL-R2 are currently in clinical trials (270). Studies are ongoing 
in the Foreman laboratory to investigate combining MRK003 and TRAIL as a means to 
eliminate the breast CSC.  
 
 We observed that inhibition of the JNK pathway and the p38 MAPK pathway 
were able to reverse the effects of MRK003 on mammosphere formation indicating that 
these pathways may play a role in apoptosis of mammospheres. The JAK2/EGFR 
kinase inhibitor (AG490) and the MEK-1 inhibitor (PD98059), however, were not able to 
reverse the effects of MRK003. Interestingly, the NF-κB inhibitor did not reverse the 
effects of MRK003, but it was able to prevent mammosphere formation. This is not 
surprising because NF-κB is a downstream target of Notch in the non-canonical 
pathway. Furthermore, treatment with NF-κB inhibitors was shown to decrease 
proliferation of mammospheres derived from MCF7 cells, as well as, decreased the SP 
fraction (245).  
 
Interestingly, the Notch and p38 MAPK pathway have been shown to interact in 
skeletal muscle differentiation (myogenesis). Activated Notch was shown to induce 
expression of mitogen activated protein kinase phosphatases-1 (MKP-1), which is a 
dual-specificity phosphatase that dephosphorylates and inactivates p38 MAPK 
preferentially in skeletal muscle (271). This is an interesting hypothesis to pursue since 
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both the JNK and p38 MAPK pathways are somewhat redundant in that they are 
involved in apoptosis and survival.  
 
The role of MKP-1, -2 has been explored in breast cancer tumors. Malignant and 
non-malignant samples were taken from patients who had primary breast cancer and 
assayed for MAPK activity and the presence of MKP-1, and -2. Expression and activity 
of MKP-1, -2 were compared to a non-malignant sample from the same patient. The 
results showed that the tumors had a 3-fold increase in expression and activity of p38 
MAPK and 2.5-fold increase in JNK-1. However, the activity of JNK was decreased in 
malignant samples. This discrepancy was further tested by looking at the levels of MKP-
1 and MKP-2, which were found to be significantly upregulated compared to non-
malignant tissue. These would then dephosphorylate JNK and lead to its lower activity 
thereby preventing the expression of apoptotic genes. Therefore, suppressing MKP-1 
and MKP-2 may prove useful in the clinic (272).  
 
Finally, while we have shown that apoptosis is occurring in MRK003 treated 
mammospheres, in part through the extrinsic pathway and that JNK, and p38 MAPK 
may be involved in apoptosis we have not ruled out the possibility that cells are dying by 
mitotic catastrophe, necrosis, or autophagy. The easiest way of ruling out mitotic 
catastrophe is by examining the nuclei of mammosphere cells and determining if they 
are micronucleated, which is characteristic of mitotic catastrophe. Further studies can be 
done to see if cells have arrested in G2 or M phase of the cell cycle. One way of doing  
this is by determining the mitotic index, which can be done by staining mammospheres 
with mitotic protein monoclonal-2 antibodies that identify proteins that are 
phosphorylated only during the M-phase (189). Some of these proteins include Hsp70, 
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cdc25, and DNA topoisomerase IIa. If cells express high levels of phosphorylation of 
these targets that would indicate they are undergoing mitotic catastrophe. To distinguish 
necrosis from apoptosis one can look at swelling and bursting of the cell consistent with 
necrosis by electron microscopy. Furthermore, since necrosis is not dependant on 
caspases it is unlikely that it is the major pathway occurring after MRK003 treatment, as 
several caspases were upregulated. Autophagy can be distinguished by using a GFP 
tagged-LC3 protein. This protein is found on the membranes of autophagosomes. They 
can be detected by fluorescence microscopy (reviewed in (273)). 
 
Our results show an important role for Notch in the survival, proliferation and self-
renewal of the breast cancer stem-like population. We have shown elevated levels of 
activated Notch in the putative CSC using three different techniques to enrich for the 
stem-like cells: SP, mammosphere formation, and Aldefluor staining. Inhibition of Notch 
signaling with GSIs resulted in growth arrest or, in the case of MRK003, apoptosis of the 
putative CSC. As GSIs are currently in clinical trials for breast cancer, our data support 
the notion that Notch may be a useful target for the treatment of breast cancer. One 
major problem in treating breast cancer is the fact that tumors are heterogeneous and 
generally contain both ERα-positive and ERα-negative cells, and studies have shown 
that approximately 20 - 30% of women with ERα-positive primary tumors develop ERα-
negative metastasis (274, 275). Butler et al. simultaneously measured ER and PR status 
in women with node-positive breast cancer and reported 25% with ERα-positive primary  
tumors had an ERα-negative nodal metastasis (276).  As MRK003 was able to eliminate 
the CSC from both ERα-positive and ERα-negative, Notch inhibition may be better able 
to CSCs in wide variety of breast cancer patients. Our data also show that treatment with 
MRK003 upregulated members of the TNFα pathway including TNF-R1 and 
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downregulated of several targets including Caspase-2, Bcl2 and Akt. Akt is involved in 
survival and can also inhibit caspase-9 by phosphorylation (277). While Bcl2 is a pro-
survival protein and caspase-2 can cleave Bid to t-Bid. These data are consistent with 
an induction of apoptosis as some pro-survival members are downregulated. It is unclear 
whether caspase-2 plays an important role in the induction of apoptosis in our model 
since its downstream target Bid was not affected at the mRNA level, however, it may be 
affected at the protein level.  
 
Our data implicate the JNK and p38 MAPK in MRK003 induced effects. Several 
lines of evidence support a role for JNK in MRK003 induced effects. JNK can be 
activated through TNF-R1 by recruiting adaptor proteins TRAF2, which can bind ASK-1 
then activate MKK4/7 and JNK (228). JNK can also inhibit Bcl2 and promote the release 
of cytochrome c by mobilizing Bax to the mitochondria after phosphorylation of an 
anchor protein 14-3-3 (278). Also, we saw upregulation of the DNA-damage inducing 
agent GADD45 and RIPK2, which have been shown to modulate JNK activity (222, 279). 
Therefore, strong evidence exists to support a role for JNK in MRK-induced apoptosis. 
 
Our research supports an important role for Notch in the survival, proliferation 
and self-renewal of the putative CSC population. Notch inhibition using MRK003 was  
effectively killed the progenitor and stem like cells derived from breast cancer cell lines 
and primary samples. These studies may help us in understanding the complex biology 
of the putative CSC so that we can design better targeted therapies to kill these cells.   
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Figure 22: Summary and proposed model (A) Notch ligands such as Delta or Jag 
are expressed at a higher level in the putative CSC population (mammospheres) 
vs bulk cells. Activated Notch was elevated in this population as determined by 
the expression of direct targets of Notch, the Hes and Hey family of genes. This 
can lead to survival proliferation and self-renewal of the putative CSC. Treatment 
with a GSI decreased downstream targets of Notch. GSIs also prevented 
mammosphere proliferation and self-renewal. One GSI MRK003 induced 
apoptosis in mammospheres. Addition of a Notch decoy or an siNotch-1 RNA 
also decreased proliferation and self-renewal.  
 
(B) The apoptotic pathway induced by MRK003 includes the TNF-receptor death 
pathway. Several caspases including caspase 8/10 and caspase-9 were 
upregulated. Additionally, the JNK pathway and/or the p38 MAPK pathway may 
be involved in MRK003 induced effects. These pathways can be activated 
through the TNF-receptor pathway. Several proteins that activate JNK including 
RIPK2 and GADD45 were upregulated at the mRNA level. Furthermore, several 
proteins that are associated with survival, Akt and Bcl2, were downregulated at 
the mRNA level.  
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